Contents lists available at ScienceDirect

# Current Therapeutic Research

journal homepage: www.elsevier.com/locate/curtheres

# Effects of Ramosetron on Nausea and Vomiting Following Spinal Surgery: A Meta-Analysis



# Yiyun Lin, MD\*, Sun Tiansheng, MMS, Zhang Zhicheng, Chen Xiaobin, Li Fang

Department of Orthopedic Surgery, Senior Department of Orthopedics, the Fourth Medical Center of PLA General Hospital, Beijing, China

### ARTICLE INFO

Article history: Received 23 October 2021 Accepted 17 March 2022

Keywords: Postoperative nausea and vomiting postsurgical pain serotonin antagonists spinal surgery

# ABSTRACT

*Background:* Spinal surgery is associated with severe pain within the first few days after surgery. Opioids are commonly used to control postoperative pain, but these can lead to postoperative nausea and vomiting (PONV). Therefore, use of more effective and better-tolerated agents would be beneficial for these patients. Serotonin receptor antagonists, such as ramosetron, have been used to reduce PONV in patients receiving anesthesia.

*Objective:* We conducted a meta-analysis of published randomized controlled trials (RCTs) to compare the efficacy and tolerance of ramosetron to prevent PONV after spinal surgery.

*Methods*: Medline, Embase, Cochrane Library, and Science Citation Index databases were systematically searched for relevant RCT articles published between January 1979 and November 2020. Full text articles restricted to English language that described RCTs comparing the use of ramosetron with other serotonin antagonists to treat PONV following spinal surgery in adult patients were considered for meta-analysis. Two reviewers independently performed study selection, quality assessment, and data extraction of all articles. Differences were resolved by a third reviewer.

*Results:* The search identified 88 potentially relevant articles, of which only 3 met our selection criteria. Study drugs were administered at the end of spinal surgery in all 3 included articles. The meta-analysis revealed that ramosetron (0.3 mg) reduced the pain score (mean difference = -0.66; 95% CI -1.02 to -0.30), lowered the risk of PONV (risk ratio = 0.86; 95% CI, 0.76-0.97), and postoperative vomiting (risk ratio = 0.32; 95% CI, 0.17-0.60), and limited the use of rescue antiemetics (risk ratio = 0.66; 95% CI, 0.45-0.96) after spinal surgery. However, there were no significant differences in the incidence of postoperative nausea, the use of rescue pain medications, the number of rescue analgesics required, and the risk of discontinuation of patient-controlled analgesia between ramosetron and palonosetron (0.075 mg) or ondansetron (4 mg). There were no statistically significant differences in the risk of adverse events among the 3 medications.

*Conclusions:* This meta-analysis of 3 RCTs showed that ramosetron reduced the risk of PONV and POV, limited the use of rescue antiemetics, reduced the postoperative pain score, and did not increase the risk of discontinuing patient-controlled analgesia compared with palonosetron or ondansetron after spinal surgery in 3 RCTs. Therefore, this meta-analysis indicates that ramosetron is an effective and well toler-ated antiemetic that can be used to prevent PONV following spinal surgery in adult patients. PROSPERO identifier: CRD42020223596 (*Curr Ther Res Clin Exp.* 2022; 83:XXX–XXX)

© 2022 Elsevier HS Journals, Inc.

© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND licenses (http://creativecommons.org/licenses/by-nc-nd/4.0/)

# Introduction

Pain is the second most common complaint following surgery and general anesthesia. Adequate pain management in patients following spinal surgery facilitates early mobilization and expedites hospital discharge.<sup>1</sup> However, the perioperative use of anesthesia and analgesics for pain control is a major risk factor for postoperative nausea and vomiting (PONV). PONV is defined as any nau-

0011-393X/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)



**Review Article** 

<sup>\*</sup> Correspondence to: Lin Yiyun, MD, Department of Orthopedic Surgery, Senior Department of Orthopedics, the Fourth Medical Center of PLA General Hospital, Nanmengcang 5#, Beijing, China, 100700, Tell: +86 010 84008002; fax: +86 010 84008002

*E-mail address:* a\_yun@hotmail.com (Y. Lin).

https://doi.org/10.1016/j.curtheres.2022.100666

sea, vomiting, or emesis in the postanesthesia care unit (PACU) or during the first 24 to 48 hours following surgery.<sup>2,3</sup> PONV is a distressing complication and can result in dehydration, electrolyte imbalance, acid-base imbalance, pulmonary aspiration, pneumothorax, hypoxia, suture rupture, wound dehiscence, bleeding, delay in the ability to resume oral intake, delayed postoperative recovery, and increased medical costs.<sup>2,4</sup>

Serotonin (5-hydroxytryptamine 3 [5-HT3]) receptor antagonists, such as ondansetron, granisetron, and dolasetron, are frequently used for PONV prophylaxis.<sup>4,5</sup> These antagonists have a considerably short duration of action and are thus commonly used in the immediate postoperative period, but they are less effective at preventing postoperative vomiting (POV) than postoperative nausea (PON).<sup>6</sup> Several meta-analyses have reported that an intravenous dose of the serotonin antagonist ramosetron (0.3 mg) has better efficacy and longer duration of action than other serotonin receptor antagonists after nonorthopedic surgery.<sup>7,8</sup> The incidence of PONV after orthopedic surgery is significantly reduced with antiemetic treatment.<sup>2-4</sup> Following joint surgery, ramosetron was shown to effectively reduce early PON or POV.9-12 Palonosetron was also shown to reduce the total incidence of PONV in patients receiving fentanyl patient-controlled analgesia (PCA) after orthopedic surgery.<sup>4</sup> Some studies have found that ramosetron is more effective than palonosetron in reducing the severity of PONV after spinal surgery.<sup>13,14</sup> However, it is unclear whether or not ramosetron is superior to other serotonin antagonists in preventing PONV following spinal surgery. This meta-analysis was performed to investigate whether or not ramosetron is effective and well tolerated for preventing PONV after spinal surgery in adult patients.

# **Materials and Methods**

#### Search strategy and study selection

Our protocol is registered with PROSPERO (CRD42020223596). Two researchers independently performed a comprehensive literature search of Embase, Medline, Cochrane Library, and Science Citation Index databases for relevant articles published in English between January 1979 and November 2020. A basic search was performed using the following key words: (((((PONV) OR postoperative) OR postanesthetic) OR postanaesthetic) OR surgical)) AND ((((nausea) OR vomiting) OR emesis) OR retching) AND ((((lumbar surgery) OR spinal surgery) OR lumbar spine surgery) OR cervical surgery) AND ((ramosetron) OR (serotonin antagonist)). Relevant articles were further reviewed using the following study inclusion criteria: original research comparing ramosetron with another serotonin antagonists following spinal surgery in patients aged 18 years or older, randomized controlled trials (RCTs), studies in which ramosetron and a serotonin antagonist were administered intravenously, and availability of full text (detailed information).

#### Data extraction and quality assessment

Data from the studies were extracted by 2 reviewers (L.Y.Y. and C.X.B.). Differences were resolved by a third reviewer (Z.Z.C.). The following information was extracted from each article: author, year of publication, study design, number of patients, type of surgery, dose of ramosetron or an alternative serotonin antagonist, time of administration of the experimental drug, and definition of the postoperative period. The following results were extracted if reported: number of cases of PONV, PON, and POV in general and during different postoperative phases (PACU, postoperative 0 to 6 hours, 6 to 24 hours, 24 to 48 hours, and 48 to 72 hours), postoperative pain score, need for rescue antiemetics or rescue analgesics, and incidence of adverse effects related to study drugs, such as headache, dizziness, drowsiness, and cardiac events. If available,

data on the ratio of relative risks and differences between treatment agents for categorical and continuous outcomes, respectively, were extracted from all publications. Categorical outcomes are reported as risk ratios (RRs) and their corresponding 95% CIs, and continuous outcomes are reported as weighted mean difference (MD). A *P* value < 0.05 was considered statistically significant.

Two authors (L.Y.Y. and C.X.B.) independently assessed the quality of the studies and assigned a numerical score between 0 and 7 as an estimated measure of the quality of the study (Table 1). The quality of the included studies was evaluated using the Newcastle-Ottawa scale (www.ohri.ca/programs/clinical\_epidemiology/oxford. htm). The score considered study design, patient selection, randomization, assessment (grade) of nausea or/and vomiting, definition of outcomes, statistical method, and power analysis (0 being the weakest and 7 being the strongest). Differences were resolved by discussion and consensus. If disagreement persisted, all listed authors were consulted.

# Statistical analysis

When 2 or more studies reported outcomes of interest, effect estimates were combined with meta-analyses in Review Manager version 5.3 (The Cochrane Collaboration, London, United Kingdom). Statistical heterogeneity between trials was evaluated using the Cochran  $\chi^2$  statistic and was considered significant when the *P* value was 0.1. When there was statistical heterogeneity, a random-effect model was used for analysis. In the absence of statistically significant heterogeneity, only the fixed-effect model was used.

To further test the robustness of the results, several sensitivity analyses were performed a priori. First, we evaluated whether or not the statistical method (random-effect model vs fixed-effect model) would influence the results. Second, we determined whether or not the quality of the publication (high or low quality) could influence the results of the meta-analysis. In addition, a subgroup analysis was performed according to different criteria (eg, high and low dose of the drug used). When the data were not presented in a manner that could be included in the meta-analysis or when only 1 study was identified for a given outcome, the results of individual studies are presented.

#### Results

# Included studies

The literature search retrieved 88 potentially relevant articles from Embase, Medline, the Cochrane Library, and the Science Citation Index databases. After removing duplicate articles and reviews, 70 studies were eligible for inclusion in this meta-analysis (Figure 1). All abstracts from these publications were screened for ramosetron, PONV, and spinal surgery. Of the 70 studies, 52 studies did not administer ramosetron, 9 did not report postspinal surgery, 3 had patients younger than age 18 years, and 3 did not compare ramosetron with a serotonin antagonist in patients receiving spinal surgery. These studies were excluded from the analysis. The 3 remaining articles met the study criteria and were included in this meta-analysis.

#### Description of the included articles

Details of the included studies are presented in Table 2. The smallest study included 94 patients,<sup>15</sup> and the largest study included 296 patients.<sup>13</sup> Two studies compared ramosetron (0.3 mg) with palonosetron (0.075 mg),<sup>13,14</sup> whereas 1 study compared ramosetron with ondansetron (4 mg).<sup>15</sup> In all included articles, study drugs were administered at the end of spinal surgery. Song et al<sup>13</sup> administered the drug 20 minutes before the end of surgery

#### Table 1

Quality score of included studies.

First author (year of publication, country)	Study design	Patient selection	Randomization	Nausea or/and vomiting assessment	Definition of outcomes	Statistical tool	Power analysis	Total score
Choi <sup>15</sup> (2008, Republic of Korea)	1	1	1	1	1	1	1	7
Roh <sup>14</sup> (2014, Republic of Korea)	1	1	1	1	1	1	1	7
Song <sup>13</sup> (2017, Republic of Korea)	1	1	1	1	0	1	1	6




Figure 1. Study selection process.

and 24 hours after surgery; Roh et al<sup>14</sup> administered the drug 10 minutes before the end of surgery; and Choi et al<sup>15</sup> administered the drug at the end and 24 hours after surgery, but the specific time point at the end of surgery was not provided. The postoperative period was defined as 0 to 48 hours after surgery in 2 studies<sup>13,15</sup> and 0 to 72 hours in another.<sup>14</sup>

### Outcomes of the pooled studies

Meta-analysis revealed that ramosetron significantly reduced the risk of PONV (RR = 0.86; 95% CI, 0.76-0.97; P = 0.01) (Figure 2A) and POV (RR = 0.32; 95% CI, 0.19–0.56; P < 0.0001) (Figure 2B). In the subgroup analysis, ramosetron reduced the risk of PONV (RR=0.85; 95% CI, 0.74-0.99; P=0.03) compared with palonosetron, but not compared with ondansetron. Treatment with ramosetron did not reduce the incidence of POV (24-48 hours: RR = 1.00; 95% CI, 0.21-4.87; P = 1.00; 48-72 hours: RR = 0.33; 95% CI, 0.01–8.08; P=0.50) (Figure 2B), PON (total postoperative period: RR = 0.95; 95% CI, 0.74-1.22; P = 0.69; during PACU: RR = 0.78; 95% CI, 0.41-1.47; P = 0.44; 0-6 hours: RR = 1.02; 95% CI, 0.69–1.50; P = 0.93; 6–24 hours: RR = 0.95; 95% CI, 0.80–1.13; P = 0.53; 24–48 hours: RR = 0.72; 95% CI, 0.49–1.05; P = 0.09; 48– 72 hours: RR = 2.00; 95% CI, 0.71-5.64; P = 0.19) (Figure 2C) compared with palonosetron or ondansetron. The pooled data showed that ramosetron significantly lowered the risk of POV during the first postoperative 24 hours (0-6 hours: RR = 0.17; 95% CI, 0.06-0.52; P = 0.002; 6-24 hours: RR = 0.41; 95% CI, 0.19-0.86; P = 0.02) and limited the use of rescue antiemetics (RR = 0.66; 95% CI, 0.45–0.96; P = 0.03) (Figure 3A).

Significant heterogeneity was observed in PON and POV during various postoperative phases among the pooled studies. Therefore, a random-effects model was used for these analyses. Pooled data analyses showed that ramosetron reduced the postoperative pain score (MD = -0.66; 95% CI, -1.02 to -0.30; P = 0.0004) postoperative time period analyses: (0-6 hours: MD = -0.61; 95% CI,-1.08 to -0.14; P = 0.01; 6-24 hours: MD = -0.70; 95% CI, -1.16to -0.24; P = 0.003; 24-48 hours: MD = -1.20; 95% CI, -2.28 to -0.13; P < 0.00001; 48-72 hours: MD = -0.80; 95% CI, -1.33 to -0.27; P = 0.003) (Figure 3B). However, ramosetron did not reduce the PACU pain score (MD = 0.10; 95% CI, -0.33 to 0.53; P = 0.65) or use of rescue pain medications (MD = -9.43; 95% CI, -32.30 to 13.44; P = 0.42 (see Supplemental Figure 1A in the online version at doi:10.1016/j.curtheres.2022.100666) following spinal surgery. In addition, ramosetron did not increase the risk of PCA discontinuation (RR = 0.76; 95% CI, 0.41-1.40; P = 0.38) (see Supplemental Figure 1B in the online version at doi:10.1016/j.curtheres.2022. 100666) or the use of rescue analgesics (RR = 0.90; 95% CI, 0.58-1.40; P = 0.65) (see Supplemental Figure 1C in the online version at doi:10.1016/j.curtheres.2022.100666) compared with other serotonin antagonists.

There were no statistically significant differences in the risk of total adverse events between the three medications (RR = 1.10; 95% CI, 0.80–1.51; P = 0.54) (see Supplemental Figure 2A in the online version at doi:10.1016/j.curtheres.2022.100666). Further-

#### Table 2

Characteristics of included studies.

First author (year of publication, country)	Surgery type	No. of patients	Age $\pm$ SD, y	Risk factors of PONV $\pm$ SD	Type of anesthesia	Treatment	Time of administration	Definition of postoperative period
Choi <sup>15</sup> (2008, Republic of Korea)	Lumbar spine	94	Group R 49 ± 9; group 0 51 ± 11	≥3	General anesthesia	R (0.3 mg); O (4 mg)	End of surgery and 24 h after surgery	0–6 h, 6–24 h, and 24–48 h
Roh <sup>14</sup> (2014, Republic of Korea)	Lumbar spinal	196	Group R 49 ± 13; group P 49 ± 14	Group R 1.9 ± 0.6; Group P 1.9 ± 0.7	General anesthesia	R (0.3 mg); P (0.075 mg)	10 min before the end of surgery	Intervals of 0–6 h, 6 –24 h, 24–48 h, and 48–72 h
Song <sup>13</sup> (2017, Republic of Korea)	Cervical laminoplasty, cervical anterior interbody fusion, lumbar laminectomy, posterior lumbar interbody fusion, benign spinal cord tumor removal	296	Not provided	Not provided	General anesthesia	R (0.3 mg); P (0.075 mg)	20 min before the end of surgery and 24 h after surgery	Early (0–6 h) and late (6–48 h)

O = ondansetron; P = palonosetron; PONV = postoperative nausea and vomiting; R = ramosetron.

more, ramosetron had no effect on the incidence of headache (RR=0.78; 95% CI, 0.44–1.41; P=0.41) (see Supplemental Figure 2B in the online version at doi:10.1016/j.curtheres.2022.100666), dizziness (RR=0.94; 95% CI, 0.59–1.49; P=0.78) (see Supplemental Figure 2C in the online version at doi:10.1016/j.curtheres.2022.100666), or drowsiness (RR=1.17; 95% CI, 0.78–1.75; P=0.45) (see Supplemental Figure 2D in the online version at doi:10.1016/j.curtheres.2022.100666)). Roh et al<sup>14</sup> found no difference in the incidence of constipation, urinary retention (P=0.516), or pruritus (P=1.000) between ramosetron and palonosetron, and Song et al<sup>13</sup> reported no difference in the incidence of palpitation (P > 0.999).

# Publication bias and sensitivity analyses

The funnel plot showing PON as an end point indicates the presence of publication bias (see Supplemental Figure 3 in the online version at doi:10.1016/j.curtheres.2022.100666)). This bias could be attributed to the following factors. First, the postoperative periods were divided differently in the 3 articles. Roh et al<sup>14</sup> evaluated the pain score in the PACU and at postoperative intervals of 0 to 6 hours, 6 to 24 hours, 24 to 48 hours, and 48 to 72 hours; Choi et al<sup>15</sup> subdivided the postoperative phase into 3 time periods (0 to 6 hours, 6 to 24 hours, and 24 to 48 hours), and Song et al<sup>13</sup> divided the postoperative phase into early (0 to 6 hours) and late (6 to 48 hours). Second, surgery in the study by Song et al<sup>13</sup> included lumbar spinal surgery, as well as cervical and benign spinal cord tumor operations; the other 2 studies included only lumbar surgery.<sup>14,15</sup> (Results of sensitivity analyses were similar regardless of the effect model applied (Table 3).

# Discussion

This meta-analysis of only three RCTs found that ramosetron was associated with a lower risk of PONV, POV, and the use of rescue antiemetics compared with palonosetron or ondansetron following spinal surgery. The analysis also demonstrated that ramosetron was effective at reducing the postoperative pain score and did not increase the risk of PCA discontinuation or postoperative adverse events compared with palonosetron or ondansetron after spinal surgery in adult patients. No significant differences were found in the incidence of PON, the use of rescue analgesics, or the number of pain medications required between ramosetron and palonosetron or ondansetron. Ramosetron has a significantly higher binding affinity for 5-HT3 receptors and a slower receptor dissociation rate than the conventional serotonin receptor antagonist ondansetron. As a result, ramosetron is a more potent antagonist. In contrast, palonosetron has a higher binding affinity (>30-fold) for the 5-HT3 receptor compared with ramosetron or ondansetron.<sup>16,17</sup> Because of the short half-life of most 5-HT3 receptor antagonists, these medications are typically administered at the end of surgery. Tong et al<sup>2,18</sup> administered ramosetron or ondansetron at the end of the surgery, but palonosetron at the beginning to manage PONV. However, because the length of spinal surgery is not constant, administration of 5-HT3 receptor antagonists before or at the beginning of surgery is not necessarily effective for preventing PONV. Thus, in this meta-analysis only studies that administered antiemetics at the end of spinal surgery were included.

Compared with regional anesthesia, general anesthesia is associated with a higher incidence of PONV and a greater use of opioids to control postoperative pain following spinal surgery. Elvir-Lazo et al<sup>2</sup> reported that the risk of PONV increases by 60% with every additional 30 minutes of surgical procedures. The highest incidence of PONV occurs within the first days after surgery.<sup>19</sup> In our analysis, ramosetron lowered the risk of PONV compared with palonosetron or ondansetron, which could be attributed to ramosetron being administered postoperatively rather than preoperatively. Our analysis also showed a lower risk of POV during the first 24 hours of postoperative care, but not after 24 hours. Unlike the results of POV, there were no differences in PON in any of the postoperative periods, which could be partially attributed to the qualitative assessment of nausea rather than the quantitative measurement of PON. Although POV is generally assessed as a dichotomous variable of "yes" or "no," PON can be assessed according to severity (mild-moderate-severe) on a Likert or visual analog scale. The method used is clinically important, because "mild nausea" may not require any rescue antiemetics, whereas moderateto-severe nausea often does, making this a more relevant method in clinical practice from the patient's perspective.

It is well known that spinal surgery is associated with severe pain within the first few days after surgery, and that this pain is often managed with opioids.<sup>14</sup> Multimodal analgesics have been proposed to effectively reduce postoperative pain, but these agents can prolong gastric emptying time and possibly contribute to abdominal complications, such as emesis, after spinal surgery.<sup>20</sup> Certain types of surgeries (eg, neurosurgery, abdominal, ophthalmic,

Study or Subgroup I.1.1 Ramosetron vs.	Events	tron Total	Palonosetron/Ondan Events	setron <u>T</u> otal	Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
	Palonose	tron					
toh (2014) long (2017)	49 90	98 150	66 94	98 146	32.3% 46.6%	0.74 [0.58, 0.94] - 0.93 [0.78, 1.11]	
otal events	139	248	160	244	78.9%	0.85 [0.74, 0.99]	
otal events leterogeneity: Chi² = est for overall effect:	2.22, df = 1	I (P = 0	.14); I <sup>2</sup> = 55%				
.1.2 Ramosetron vs			<i>'</i>				
choi (2008)	38	47	43	47 47	21.1%	0.88 [0.75, 1.04] 0.88 [0.75, 1.04]	
otal events	38	47	43	4/	21.1%	0.00 [0.75, 1.04]	
leterogeneity: Not ap est for overall effect:	plicable Z = 1.48 /F	P = 0.14	)				
	2-1.100	295	/	204	100.0%	0.86 [0.76, 0.97]	
'otal (95% CI) 'otal events	177		203	291	100.0%	0.86 [0.76, 0.97]	
leterogeneity: Chi² = 'est for overall effect:	Z = 2.50 (F	P = 0.01	)			-	0.7 0.85 1 1.2 1.5 Favours (experimental) Favours (control)
est for subaroup all	erences: C	:nr= 0.	09. df = 1 (P = 0.76). I <sup>a</sup>	= 0%			
В	Ramose		Palonosetron/Ondan			Risk Ratio	Risk Ratio
tudy or Subgroup .2.1 PACU	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Roh (2014)	0	98	0	98		Not estimable	
Subtotal (95% CI) Total events	0	98	0	98		Not estimable	
leterogeneity: Not ap est for overall effect:	plicable	able					
		ອມເຮັ					
.2.2 Postop- 0-6 hou Choi (2008)	rs 2	47	9	47	18.3%	0.22 [0.05, 0.97]	
Roh (2014)	0	98	5	98	11.2%	0.09 [0.01, 1.62] +	
Song (2017) Subtotal (95% CI)	1	150 295	7	146 291	14.4% 43.9%	0.14 [0.02, 1.12] 0.16 [0.05, 0.49]	-
otal events leterogeneity: Chi² =	0 35 df= 3	7 (P = 0	21 84): I <sup>2</sup> = 0%				
est for overall effect:	Z = 3.22 (F	P = 0.00	11)				
.2.3 Postop- 6-24 ho	urs						
Choi (2008) Roh (2014)	5	47 98	11	47	22.4%	0.45 [0.17, 1.21] 0.17 [0.02, 1.36]	
long (2017)	1	150	6	146	12.4%	0.49 [0.12, 1.91]	
Subtotal (95% CI) Total events	9	295	23	291	46.9%	0.39 [0.19, 0.81]	-
leterogeneity: Chi <sup>a</sup> = 'est for overall effect:	0.83, df = 1	2 (P = 0 P = 0.01	.66); I <sup>2</sup> = 0%				
.2.4 Postop- 24-48 h							
hoi (2008)	1	47	1	47	2.0%	1.00 [0.06, 15.52]	
Roh (2014) Subtotal (95% CI)	2	98 145	2	98 145	4.1% 6.1%	1.00 [0.14, 6.96] 1.00 [0.21, 4.87]	
"otal events Heterogeneity: Chi <sup>2</sup> =	3 0.00. df = 1	I(P= 1	3 .00):  ² = 0%				
est for overall effect:	Z = 0.00 (F	P = 1.00	)				
.2.5 Postop- 48-72 h	ours						
Roh (2014) Subtotal (95% CI)	0	98 98	1	98 98	3.1% 3.1%	0.33 [0.01, 8.08] 0.33 [0.01, 8.08]	
otal events	0	50	1	50			
Heterogeneity: Not ap		e = 0.50	0				
Fest for overall effect:				023	100.0%	0.32 [0.19, 0.56]	•
		034			100.0%	3.32 [0.19, 0.30]	-
Fest for overall effect: Fotal (95% CI) Fotal events	15	931	48				
otal (95% CI) otal events Heterogeneity: Chi² =	15 4.76, df=1	B (P = 0	.78); I <sup>2</sup> = 0%			L 0	.01 0.1 1 10 100
otal (95% CI) otal events leterogeneity: Chi <sup>2</sup> = est for overall effect:	15 4.76, df = 1 Z = 4.03 (F	B (P = 0 P < 0.00	.78); I <sup>2</sup> = 0%	= 17.5%		L 0	.01 0.1 1 10 100 Favours (experimental) Favours (control)
iotal (95% CI) iotal events leterogeneity: Chi <sup>2</sup> = iest for overall effect: iest for subαroup diff	15 4.76, df = 1 Z = 4.03 (F	8 (P = 0 < 0.00 chi <sup>2</sup> = 3.	.78); I <sup>2</sup> = 0% (01)			Risk Ratio	Favours (experimental) Favours (control) Risk Ratio
Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff	15 4.76, df = 1 Z = 4.03 (F erences: C	8 (P = 0 < 0.00 chi <sup>2</sup> = 3.	.78); I <sup>2</sup> = 0% (01) 64. df = 3 (P = 0.30). I <sup>2</sup>		Weight		Favours (experimental) Favours (control)
total (95% CI) total events leterogeneity: Chi <sup>a</sup> = test for overall effect: test for subaroup diff total over <u>Subgroup</u> 1.1 PACU toth (2014)	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose	8 (P = 0 < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u> 98	.78); I <sup>2</sup> = 0% (01) 64. df = 3 (P = 0.30). I <sup>2</sup> Palonosetron/Ondan	setron <u>Total</u> 98	5.3%	Risk Ratio M-H, Random, 95% CI 0.78 [0.41, 1.47]	Favours (experimental) Favours (control)  Risk Ratio  M-H, Random, 95% CI
iotal (95% CI) iotal events Heterogeneity: Chi <sup>a</sup> = rest for overall effect: rest for subgroup diff intudy or Subgroup 1.1 PACU Roh (2014) Subtotal (95% CI)	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose <u>Events</u> 14	8 (P = 0 < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u>	.78);  ² = 0%  01)  64, df = 3 (P = 0.30),  ²  Patonosetron/Ondan  Events	setron Total		Risk Ratio M-H, Random, 95% CI	Favours (experimental) Favours (control)  Risk Ratio  M-H, Random, 95% CI
otal (95% CI) 'otal events leterogeneity: Chi <sup>a</sup> = 'est for overall effect: 'est for subaroup diff .tudy or Subgroup .t.1 PACU toh (2014) iubtotal (95% CI) otal events leterogeneity: Not ap	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose <u>Events</u> 14 14 14 14	8 (P = 0 P < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u> 98 98	.78);  P = 0% 01) 64, df = 3 (P = 0.30).  P Palonosetron/Ondan Events 18 18	setron <u>Total</u> 98	5.3%	Risk Ratio M-H, Random, 95% CI 0.78 [0.41, 1.47]	Favours (experimental) Favours (control)  Risk Ratio  M-H, Random, 95% Cl
otal (95% CI) otal events teterogeneity: Chi <sup>2</sup> = est for overall effect est for subaroup diff ditudy or Subaroup 1.1 PACU toh (2014) ubtotal (95% CI) otal events teterogeneity: Not ap est for overall effect	15 4.76, df = 4 Z = 4.03 (f erences: C Ramose <u>Events</u> 14 14 14 2 = 0.77 (f	8 (P = 0 P < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u> 98 98	.78);  P = 0% 01) 64, df = 3 (P = 0.30).  P Palonosetron/Ondan Events 18 18	setron <u>Total</u> 98	5.3%	Risk Ratio M-H, Random, 95% CI 0.78 [0.41, 1.47]	Favours (experimental) Favours (control)  Risk Ratio  M-H, Random, 95% CI
total (95% CI) Total events deterogeneity: ChiP= est for overall effect est for suboroup diff Study or Suboroup 1.1 PACU total events teterogeneity: Not ag- est for overall effect .1.2 Postop- 0-6 hou	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose <u>Events</u> 14 14 plicable Z = 0.77 (F Irs	8 (P = 0 2 < 0.00 2 ini <sup>2</sup> = 3. 1	(78);  P = 0% (01) 64, df = 3 (P = 0.30).  P Palonosetron/Ondan Events 18 18 18	setron Total 98 98	5.3% 5.3%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47]	Favours (experimental) Favours (control) Risk Ratio M.H. Random, 95% Cl
tati (95% Cl) tati events leterogeneity: ChiP = est for overall effect est for subarouo diff ChiPCU ChiPCU tatiy or Subaroup 1.1 PACU tatiy or Subaroup tatiy or Subaroup tation (2014) ubtotal (95% Cl) otal events leterogeneity: Not ap est for overall effect. 1.2 Postop- 0-6 hou hou (2014)	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose Events 14 14 14 2 = 0.77 (F rs 31 31	8 (P = 0 2 < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u> 98 98 98 P = 0.44 47 98	78); (F = 0% 101) 64. df = 3 (P = 0.30), (P Palonosetron/Ondan Events 18 18 18 ) 23 47	setron Total 98 98 98 47 98	5.3% 5.3% 11.7% 11.7%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94]	Favours (experimental) Favours (control) Risk Ratio M.H. Random, 95% Cl
total (95% CI) Total events leterogeneity: ChiP = Test for overall effect Test for subaroun diff ChiP Control (ChiP Control ChiP Control	15 4.76, df = 1 Z = 4.03 (F erences: C <u>Ramose Events</u> 14 14 14 14 2 = 0.77 (F rs 31	8 (P = 0 2 < 0.00 chi <sup>2</sup> = 3. tron <u>Total</u> 98 98 98 2 = 0.44 47	(78); (F = 0% (01) 64, df = 3 (P = 0.30), (F Patonosetron/Ondan Events 18 18 ) 23	setron Total 98 98 98	5.3% 5.3% 11.7%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.91, 1.48]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity. Chi*= est for overall effect. est for subaroun diffect. est for subaroun 1.1 PACU biol (Cata) 55% CI) otal events letterogeneity. Not ag est for overall effect. 1.1 2 Postop. 0.6 hou: hou (Cata) 5 choi (Cat	15 4.76, df = 1 Z = 4.03 (f erences: C Ramose Events 14 14 plicable Z = 0.77 (f rs 31 31 75 137	8 (P = 0 < 0.00	78); F = 0% 01) 64. df = 3 (P = 0.30). P Patonosetrom/Ondan Events 18 18 ) 23 47 63	setron Total 98 98 98 47 98 146 291	5.3% 5.3% 11.7% 11.7% 16.4%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94]	Favours (experimental) Favours (control)
otal (95% CI) otal events deterogeneity. Chi <sup>9</sup> = est for overall effect est for subbroub diffect test for subbroub L1.1 PACU Solt (2014) subtotal (95% CI) otal events deterogeneity. Not ap est for overall effect L1.2 Postop- 0-6 hou choi (2008) Solt (2017) subtotal (95% CI) otal events deterogeneity. Tau <sup>9</sup> =	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose Events 14 14 14 plicable Z = 0.77 (F rs 31 31 75 137 0.09; Chi <sup>2</sup>	8 (P = 0 2 < 0.00 hi <sup>2</sup> = 3. tron <u>Total</u> 98 98 98 98 98 29 295 = 9.14,	79); P = 0% 01) 64. df = 3 (P = 0.30). P Palonosetron: Ondan Events 18 18 ) 23 47 63 63 df = 2 (P = 0.01), P = 7	setron Total 98 98 98 47 98 146 291	5.3% 5.3% 11.7% 11.7% 16.4%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.91, 1.48]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity. Chi*= est for overall effect. est for subaroun diffect. est for subaroun 1.1 PACU biol (Cata) 55% CI) otal events letterogeneity. Not ag est for overall effect. 1.1 2 Postop. 0.6 hou: hou (Cata) 5 choi (Cat	15 4.76, df = 1 Z = 4.03 (F erences: C Ramose <u>Events</u> 14 14 14 14 plicable Z = 0.77 (F rs 31 31 75 137 0.09; Chi <sup>a</sup> Z = 0.08 (F	8 (P = 0 2 < 0.00 hi <sup>2</sup> = 3. tron <u>Total</u> 98 98 98 98 98 29 295 = 9.14,	79); P = 0% 01) 64. df = 3 (P = 0.30). P Palonosetron: Ondan Events 18 18 ) 23 47 63 63 df = 2 (P = 0.01), P = 7	setron Total 98 98 98 47 98 146 291	5.3% 5.3% 11.7% 11.7% 16.4%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.91, 1.48]	Favours (experimental) Favours (control)
otal (95% CI) otal events deterogeneity: Chi <sup>a</sup> = est for verall effect. est for subarous diff Chitek or Subarous chitek or Subarous chitek or Subarous chitek or Subarous chitek or Subarous chitek or Subarous deterogeneity. Not ap est for overall effect chitek or Subarous chitek or Subarous	15 4.76, df = 1 Z = 4.03 (f = 1 Z = 4.03 (f = 1 Events 14 14 plicable Z = 0.77 (f rs 31 31 75 137 0.09; Chi <sup>2</sup> Z = 0.08 (f uss 2 = 0.08 (f	8 (P = 0 < 0.00 ihi <sup>2</sup> = 3. tron 98 98 98 2 = 0.44 47 98 150 295 = 9.14, 2 = 0.93 47	78); P = 0% 01) 64. df = 3 (P = 0.30). P Palonosetrom/Ondan <u>Events</u> 18 18 ) 23 47 63 df = 2 (P = 0.01); P = 7 0 25	setron Total 98 98 98 47 98 146 291 8%	5.3% 5.3% 11.7% 16.4% 39.8%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.21, 1.69] 1.02 [0.68, 1.50] 1.00 [0.68, 1.46]	Favours (experimental) Favours (control) Risk Ratio M.H. Random, 95% Cl
otal (95% CI) otal events letterogeneity Chi*= estifor overall effect. Estifor subarous diff estifor subarous diff estifor subarous diffection (2014) utilitatia (95% CI) otal events est for overall effect. 1.2 Postop. 0-6 hot hot (2008) hot (2014) utilitatia (95% CI) otal events est for overall effect. 1.3 Postop. 0-62 hot hot (2008) hot (2014) tablerogeneity. Tau*= est for overall effect. 1.3 Postop. 6-624 hot hot (2008) hot (2014)	15 4.76, df = 1 Z = 4.03 (f = 1 Z = 4.03 (f = 1 Events 14 14 plicable 2 = 0.77 (f rrs 31 31 75 137 0.09; Chi <sup>p</sup> Z = 0.08 (f urs 25 30	8 (P = 0 2 < 0.00 1 hi <sup>2</sup> = 3. 1 hi <sup>2</sup> = 0.44 47 98 98 98 98 98 98 98 98 98 98	78); P = 0% 01) 84. df = 3 (P = 0.30). P PalonosetromOndan <u>Rowths</u> 18 18 ) 23 47 63 df = 2 (P = 0.01); P = 7 ) 25 38	setron Total 98 98 47 98 146 291 8% 47 98	5.3% 5.3% 11.7% 16.4% 39.8%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.44] 1.16 [0.81, 1.46] 1.02 [0.69, 1.50] 1.00 [0.68, 1.46] 0.79 [0.54, 1.16]	Favours (experimental) Favours (control) Risk Ratio M.H, Random, 95% Cl
otal (95% CI) otal events leterogenetic Chi <sup>2</sup> = set for overall effect. Set for subarous diff Set for subarous set for subarous littek or Subarous ALI PACU Not All Set for set for overall effect. Littek or Subarous Set for overall effect. Littek or Subarous Set for overall effect. Littek or Subarous Set for overall effect. Not (2014) sing (2017) sing (2017) sing (2017) sing (2017) sing (2016) Set (2014) Set (2	15 4.76, df = 1 Z = 4.03 (f erences: C Ramose Events 14 14 14 14 plicable Z = 0.77 (f rs 31 31 75 137 0.09; Chi <sup>p</sup> Z = 0.08 (f urs 25 30 75	8 (P = 0 < 0.00 Total 98 98 98 98 98 98 150 295 = 9.14, P = 0.93 47 98 47 98 98 150 295 = 9.14, P = 0.93 47 98 98 150 150 150 150 150 150 150 150	78); F = 0% 01) 84. df = 3 (P = 0.30). P Palonosetron/Ondan Events 18 18 ) 23 47 63 34 63 off = 2 (P = 0.01); P = 7 25 38 74	setron Total 98 98 98 47 98 146 291 8%	5.3% 5.3% 11.7% 16.4% 39.8%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.21, 1.69] 1.02 [0.68, 1.50] 1.00 [0.68, 1.46]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity: Chi*= est for overall effect. Est for subarous diff est for subarous diff est for subarous diffect overall effect. I.1 PACU bit of (2014) utilitatial (95% CI) otal events letterogeneity: Not ap est for overall effect. I.2 Postop- 0-6 hou hou (2016) total (2017) utilitatial (95% CI) otal events letterogeneity: Tau*= est for overall effect. hou (2016) orig (2016) total events lettorogeneity: CI) otal events lettorogeneity: CI) otal events lettorogeneity: CI) otal events lettorogeneity: CI) otal events	15 4.76, df = i Z = 4.03 (f evences: C Events 14 14 14 14 14 2 = 0.70 (f rs 31 31 31 31 31 31 31 31 31 31 31 31 31	8 (P = 0 0 < 0.00 hi <sup>2</sup> = 3, hi <sup>2</sup> = 3, tron Total 98 98 98 150 295 = 9.14, <sup>2</sup> = 0.93 47 98 150 295 = 1.07, 98 = 1.07,	78); P = 0% 01) 84. df = 3 (P = 0.30). P Palonosetron/Ondan <u>Fourits</u> 18 18 ) 23 47 63 off = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.69); P = 0	setron Total 98 98 47 98 146 291 8% 47 98 146 291	5.3% 5.3% 11.7% 16.4% 39.8%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.41] 1.6 [0.21, 1.49] 1.02 [0.69, 1.50] 1.00 [0.68, 1.46] 0.99 [0.79, 1.24]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity: Chi*= est for overall effect. Est for subarous diff est for subarous diff est for subarous diffect overall effect. I.1 PACU bit of (2014) utilitatial (95% CI) otal events letterogeneity: Not ap est for overall effect. I.2 Postop- 0-6 hou hou (2016) total (2017) utilitatial (95% CI) otal events letterogeneity: Tau*= est for overall effect. hou (2016) orig (2016) total events lettorogeneity: CI) otal events lettorogeneity: CI) otal events lettorogeneity: CI) otal events lettorogeneity: CI) otal events	15 4.76, df = i Z = 4.03 (f evences: C Events 14 14 14 14 14 2 = 0.70 (f rs 31 31 31 31 31 31 31 31 31 31 31 31 31	8 (P = 0 0 < 0.00 hi <sup>2</sup> = 3, hi <sup>2</sup> = 3, tron Total 98 98 98 150 295 = 9.14, <sup>2</sup> = 0.93 47 98 150 295 = 1.07, 98 = 1.07,	78); P = 0% 01) 84. df = 3 (P = 0.30). P Palonosetron/Ondan <u>Fourits</u> 18 18 ) 23 47 63 off = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.69); P = 0	setron Total 98 98 47 98 146 291 8% 47 98 146 291	5.3% 5.3% 11.7% 16.4% 39.8%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.41] 1.6 [0.21, 1.49] 1.02 [0.69, 1.50] 1.00 [0.68, 1.46] 0.99 [0.79, 1.24]	Favours (experimental) Favours (control)
otal (95% CI) otal events telerogeneity: Chi*= est for overall effect. Itaty or Subarouo diff taty or Subarouo diff est for overall effect. Itaty or Subarouo diffection telerogeneity. Not ag est for overall effect telerogeneity. Not ag est for overall effect telerogeneity. Not ag est for overall effect itaty or Subarouo telerogeneity. Not ag est for overall effect itaty or Subarouo telerogeneity. Tau*= est for overall effect telerogeneity. Tau*= est for overall effect telerogeneity. Tau*= est for overall effect telerogeneity. Tau*= est for overall effect telerogeneity. Tau*= est for overall effect 1.14 Postop- 24-48 H	15 76, df = [ 2 = 4.03 (F evences: C Events: 14 14 14 14 14 14 14 14 15 2 = 0.77 (F 31 31 37 75 137 0.09; Chi <sup>III</sup> 2 = 0.08 (F 130 75 130 0.00; Chi <sup>III</sup> 2 = 0.62 (F 000; Chi <sup>III</sup> )	8 (P = 0 0 < 0.000 shi <sup>2</sup> = 3. 1 tron 98 98 98 150 295 = 9.14, P = 0.93 47 78 150 295 = 9.14, P = 0.93 47 8 150 295 = 1.07, P = 0.53 	$\begin{array}{c} 70; P=0\%\\ 01)\\ 64, dr=3 \ (P=0.30), P\\ \hline \\ \hline \\ \hline \\ PalonesetronOndan\\ \hline \\ \hline \\ \hline \\ 18\\ 0 \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	setron Total 98 98 98 47 98 146 291 8% 47 98 8% 47 98 8%	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.6% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 0.66 [0.46, 0.54] 1.16 [0.81, 1.48] 1.02 [0.69, 1.50] 1.00 [0.68, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity Chi*= estifor overall effect. Littery or subarouo diff estifor subarouo diff unity or Subarouo diffectifor overall effect. Littery or Subarouo diffectifor overall effect. Litterogeneity Fau*= est for overall effect.	15 76, df = [ 2 = 4.03 (F erences. C. 2 2 = 4.03 (F erences. C. 2 2 = 0.77 (F 14 14 14 14 14 14 12 2 = 0.77 (F 13 31 31 75 13 31 75 10, 09 (Ch <sup>2</sup> 2 = 0.08 (F 70 10 10 10 10 10 10 10 10 10 1	8 (P = 0 9 < 0.00 1 + 0.	78); P = 0% 01) 84. df = 3 (P = 0.30). P Palonosetron/Ondan <u>Fourits</u> 18 18 ) 23 47 63 off = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.69); P = 0	setron Total 98 98 98 47 98 146 291 8% 47 98 8% 47 8%	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.9% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.84] 1.16 [0.81, 1.48] 1.02 [0.69, 1.50] 1.00 [0.88, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.45, 1.18]	Favours (experimental) Favours (control)
otal (95% CI) otal events leterogenetic, Chi <sup>a</sup> = est for overall effect. Littly or Subaroux diff Chine Chine est for subaroux diff Chine Chine est for subaroux differents leterogenetic, Not ap est for overall effect. I:2 Postop0-hou hini (2008)0-hou hini (2008)0-hou hini (2010) otal events leterogenetic, Tau <sup>2</sup> = est for overall effect. I:3 Postop6-24 he hoi (2008) toing (2017) uintotal (95% CI) dial events leterogenetic, Tau <sup>2</sup> = est for overall effect. I:4 Postop24-48 h hoi (2008) toin (2014) uintotal (95% CI) toin (2014) uintotal effect. I:4 Postop24-48 h hoi (2008) toin (2014) uintotal (95% CI)	15 4.76, df = 1 2 = 4.03 (f c) erences: C Ramose Events - 14 14 14 14 14 12 2 = 0.77 (f 31 37 75 31 37 75 0.09, Chi <sup>2</sup> 2 = 0.08 (f 30 75 137 137 137 137 137 137 137 137	8 (P = 0) 2 < 0.00 $10^{2} < 0.00$ $10^{2} < 0.00$ $10^{2} < 0.00$ $10^{2} < 0.00$ $10^{2} = 3.0$ $10^{2} = 3.0$	78); P = 0% 01) 84. df = 3 (P = 0.30). P Palonosetrom/Ondan <u>Events</u> 18 18 18 ) 23 47 63 of = 2 (P = 0.01); P = 7 25 36 of = 2 (P = 0.59); P = 0 17	setron Total 98 98 98 47 98 146 291 8% 47 98 146 291 %	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.6% 17.4% 39.0%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.55 [0.94, 1.93] 0.65 [0.46, 0.24] 1.65 [0.46, 0.24] 1.60 [0.68, 1.46] 0.79 [0.54, 1.50] 1.00 [0.68, 1.46] 0.99 [0.79, 0.50, 1.13] 0.95 [0.50, 1.13]	Favours (experimental) Favours (control)
otal (95% CI) otal events deltorogenetic, Chir = deltorogenetic, Chir = deltorogenetic, Chir = deltorogenetic, Chir deltorogenetic, Chir deltorogenetic, Chir deltorogenetic, Tauta deltorogenetic, Tauta	15 4,76, df = [ 2 = 4.03 (f 2 = 4.03 (f 2 = 4.03 (f 2 = 0.03 (f 1 = 1) 14 14 14 14 14 14 14 14 14 14 14 14 14	8 (P = 0 9 < 0.00 9 < 0.00 10 = 2 < 0.00 10 = 2 < 0.00 98 98 98 98 98 98 98 98 98 98	78); P = 0% 01) 64, df = 3 (P = 0.30). P PalonesetronOndan Events 18 18 22 47 63 df = 2 (P = 0.01); P = 7 25 36 74 17 26 36 74 17 27 46 74 17 29 46 46 46 46 46 46 46 46 46 46	setron Total 98 98 98 146 291 8% 47 98 84 291 8% 47 98 145	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.9% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.84] 1.16 [0.81, 1.48] 1.02 [0.69, 1.50] 1.00 [0.88, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.45, 1.18]	Favours (experimental) Favours (control)
otal (95% CI) otal events deleterogeneity: Chi*= est for overall effect. 1.1 PACU Deleterogeneity: Chi*= est for average est for average est for average est f	15 4.76, df = 1 Z = 4.03 (f Ramose	8 (P = 0 9 < 0.00 9 < 0.00 10 = 2 < 0.00 10 = 2 < 0.00 98 98 98 98 98 98 98 98 98 98	78); P = 0% 01) 64, df = 3 (P = 0.30). P PalonesetronOndan Events 18 18 22 47 63 df = 2 (P = 0.01); P = 7 25 36 74 17 26 36 74 17 27 46 74 17 29 46 46 46 46 46 46 46 46 46 46	setron Total 98 98 98 146 291 8% 47 98 84 291 8% 47 98 145	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.9% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.84] 1.16 [0.81, 1.48] 1.02 [0.69, 1.50] 1.00 [0.88, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.45, 1.18]	Favours (experimental) Favours (control)
otal (95% CI) otal events deltorogenetic, Chir = deltorogenetic, Chir = deltorogenetic, Chir = deltorogenetic, Chir deltorogenetic, Chir deltorogenetic, Chir deltorogenetic, Tauta deltorogenetic, Tauta	15 4.76, df = 1 Z = 4.03 (f Ramose	8 (P = 0 9 < 0.00 9 < 0.00 10 = 2 < 0.00 10 = 2 < 0.00 98 98 98 98 98 98 98 98 98 98	78); P = 0% 01) 64, df = 3 (P = 0.30). P PalonesetronOndan Events 18 18 22 47 63 df = 2 (P = 0.01); P = 7 25 36 74 17 26 36 74 17 27 46 74 17 29 46 46 46 46 46 46 46 46 46 46	setron Total 98 98 98 146 291 8% 47 98 146 291 8% 47 98 145 5%	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.6% 10.6% 39.0%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.64, 0.24] 1.16 [0.91, 1.48] 1.02 [0.68, 1.46] 0.79 [0.54, 1.50] 0.79 [0.54, 1.51] 0.79 [0.54, 1.51] 0.99 [0.78, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.49, 1.05]	Favours (experimental) Favours (control)
otal (95% CI) otal events letterogeneity: Chi" = est for overall effect. Litter or subarous diff est for subarous diff children est for subarous differences est for overall effect. Litterogeneity: Not ap est for overall effect. Litterogeneity: Not differents est for overall effect. Litterogeneity: Tau" = est for overall effect. Litterogeneity: Tau" = e	15 4.76, df = 1 2 - 4.02 (f) 4.76, df = 1 4.76, df = 1 4.76, df = 1 4.76, df = 1 4.76, df = 1 4.77, df = 1 14. 14. 14. 14. 14. 14. 14. 14	8 (P = 0 9 < 0.00 1 + 1 + 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2 +	78); F = 0% 01) 84. df = 3 (P = 0.30). P Palonosetroni/Ondan Events 18 18 ) 23 47 63 01 25 38 74 df = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.59); P = 0 0 0 0 5	setron Total 98 98 98 146 291 8% 47 98 84 291 8% 47 98 145	5.3% 5.3% 11.7% 16.4% 39.8% 10.9% 10.9% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.84] 1.16 [0.81, 1.48] 1.02 [0.69, 1.50] 1.00 [0.88, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.45, 1.18]	Favours (experimental) Favours (control)
otal (95% C1) otal events lettorogeneiky Chi <sup>2</sup> = estifor overall effect. Listv or Subarcoup diff Subarcoup diffection of the subarcoup diffection without and (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estifor overall effect. 1.3 Postop- 6.4 hut hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estifor overall effect. 1.3 Postop- 6.24 hut hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.4 Postop- 2.44.8 h hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.4 Postop- 2.44.8 h hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.5 Postop- 4.4-72 h on (2014) uthotal (95% C1) otal events lettorogeneiky. Not ap	15 4.76, df = 1 2 - 4.02 (df = 1 2 - 4.02 (df = 1 4.76, df = 1 14 14 12 - 2.02 (df = 1 13 13 137 137 137 137 137 137	8 (P = 0 9 < 0.00 10 × 0.00 10	78); P = 0% 01) 64, df = 3 (P = 0.30). P Palonosetron:Ondan Events 18 18 23 47 63 30 df = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.59); P = 0 17 29 df = 1 (P = 0.59); P = 0 5 5	setron Total 98 98 146 291 8% 47 8% 47 88% 47 88% 146 291 8%	5.3% 5.3% 11.7% 11.7% 16.4% 39.8% 10.9% 10.6% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.94], 1.48] 1.02 [0.69, 150] 1.00 [0.68, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.49, 1.56]	Favours (experimental) Favours (control)
otal (95% C1) otal events lettorogeneiky Chi <sup>2</sup> = estifor overall effect. Listv or Subarcoup diff Subarcoup diffection of the subarcoup diffection without and (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estifor overall effect. 1.3 Postop- 6.4 hut hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estifor overall effect. 1.3 Postop- 6.24 hut hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.4 Postop- 2.44.8 h hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.4 Postop- 2.44.8 h hol (2008) on (2014) uthotal (95% C1) otal events lettorogeneiky. Tau <sup>2</sup> = estfor overall effect. 1.5 Postop- 4.4-72 h on (2014) uthotal (95% C1) otal events lettorogeneiky. Not ap	15 4.76, df = 1 2 - 4.02 (df = 1 2 - 4.02 (df = 1 4.76, df = 1 14 14 12 - 2.02 (df = 1 13 13 137 137 137 137 137 137	8 (P = 0 9 < 0.00 10 × 0.00 10	78); P = 0% 01) 64, df = 3 (P = 0.30). P Palonosetron:Ondan Events 18 18 23 47 63 30 df = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.59); P = 0 17 29 df = 1 (P = 0.59); P = 0 5 5	setron Total 98 98 146 291 8% 47 8% 47 88% 47 88% 146 291 8%	5.3% 5.3% 11.7% 11.7% 16.4% 39.8% 10.9% 10.6% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.94], 1.48] 1.02 [0.69, 150] 1.00 [0.68, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.49, 1.56]	Favours (experimental) Favours (control)
otal (95% CI) otal events testrogeneticy Chi <sup>2</sup> = est for overall effect. testrogeneticy Chi <sup>2</sup> = est for overall effect. 1.1 PACU testrogeneticy Chi est for overall effect. 1.2 Postop. 0.6 hot testrogeneticy. Not ap est for overall effect. 1.2 Postop. 0.6 hot hot (2014) utototal (95% CI) otal events testrogeneticy. Tau <sup>2</sup> = est for overall effect. 1.3 Postop. 6.24 hot hot (2008) total events testrogeneticy. Tau <sup>2</sup> = est for overall effect. 1.4 Postop. 6.24 hot hot (2014) total events testrogeneticy. Tau <sup>2</sup> = est for overall effect. 1.4 Postop. 24.48 h hot (2008) total events testrogeneticy. Tau <sup>2</sup> = est for overall effect. 1.5 Postop. 48.72 h total (2014) otal events testrogeneticy. Not ap est for overall effect. 0.16 events testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h total events testrogeneticy. Not ap est for overall effect. 0.16 events testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h total events testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h testrogeneticy. Not ap est for overall effect. 1.5 Postop. 48.72 h testrogeneticy. Not ap est for overall effect.	4.76, df = 1 Z = 4.02, (d = 1 Ramose Events 14 uplicable Z = 0.70 (d = 1 13 13 13 75 137 0.03, Chi <sup>a</sup> 73 0.00, Chi <sup>a</sup> 2 = 0.26 (d = 1 30 10, 00, Chi <sup>a</sup> 2 = 0.26 (d = 1 31 31 75 137 10, 00, Chi <sup>a</sup> 2 = 0.26 (d = 1 13 13 13 13 13 13 13 13 13 1	8 (P = 0 9 < 0.00 10 × 0.00 10	$\begin{array}{c} 70; \ \ P = 0\% \\ 01) \\ 64, \ dr = 3 \ (P = 0.30). \ P \\ \hline Palonosetron: Ondan \\ \hline Courts \\ 18 \\ 18 \\ 18 \\ 18 \\ 18 \\ 18 \\ 18 \\ 1$	setron Total 98 98 47 98 146 291 8% 47 98 146 291 8% 47 98 145 98 98 98 98	5.3% 5.3% 11.7% 11.7% 16.4% 39.8% 10.9% 10.6% 17.4% 39.0%	Risk Ratio M.H. Random, 95% CI 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.35 [0.94, 1.93] 0.66 [0.46, 0.94] 1.16 [0.94], 1.48] 1.02 [0.69, 150] 1.00 [0.68, 1.46] 0.79 [0.54, 1.16] 0.99 [0.79, 1.24] 0.95 [0.80, 1.13] 0.71 [0.38, 1.31] 0.72 [0.49, 1.56]	Favours (experimental) Favours (control)
otal (95% C)) otal events est for overall effect. Luty or Subartous terror subartous tuty or Subartous tuty or Subartous tuty or Subartous otal events est for overall effect. 1.1 PACU otal events est for overall effect. 1.2 Postop- 0-6 hot hoi (2008) ong (2017) ong (2	A 16, d = 1 Z = 4 03 (d = 1 Ramose Events	8 (P = 0 9 < 0.00 1 + 10 + 10 + 10 + 10 + 10 + 10 + 10 +	78); P = 0% 01) 64, df = 3 (P = 0.30). P Palonosetron:Ondan Events 18 18 23 47 63 30 df = 2 (P = 0.01); P = 7 25 38 74 df = 2 (P = 0.59); P = 0 17 29 df = 1 (P = 0.59); P = 0 5 5	setron Total 98 98 47 98 146 291 8% 47 98 146 291 98 145 98 98 98 98	5.3% 5.3% 11.7% 11.7% 39.8% 10.9% 39.8% 10.9% 8.0% 13.6%	Risk Ratio <u>M.H. Random, 95% CI</u> 0.78 [0.41, 1.47] 0.78 [0.41, 1.47] 1.55 [0.94, 1.93] 0.65 [0.46, 0.24] 1.65 [0.46, 0.24] 1.60 [0.68, 1.46] 0.79 [0.54, 1.50] 1.00 [0.68, 1.46] 0.79 [0.40, 1.13] 0.71 [0.38, 1.31] 0.72 [0.49, 1.16] 0.72 [0.49, 1.65] 2.00 [0.71, 5.64]	Favours (experimental) Favours (control)

Figure 2. (A) Forrest plot of postoperative nausea and vomiting. (B) Forrest plot of postoperative vomiting. (C) Forrest plot of postoperative nausea.

oral, and maxillofacial surgeries) have a higher incidence of PONV, possibly due to prolonged exposure to general anesthesia and higher opioid use.<sup>21,22</sup> Multimodal analgesics have become increasingly popular to prevent postoperative pain, but these analgesics are frequently accompanied by critical complications, such as PONV, during the postoperative period.<sup>18</sup> Moreover, PONV can be exacerbated with the combined use of anesthesia and analgesics. This meta-analysis found that administration of ramosetron reduced the risk of PONV and POV, and limited the use of res-

cue antiemetics, as well as reduced the pain score compared with palonosetron or ondansetron during the postoperative period. However, there were no differences in PCA discontinuation, number of rescue analgesics required, or rescue pain medications administered after spinal surgery.

The most commonly noted complications in the included studies were headache, dizziness, and drowsiness. Our analysis showed that ramosetron was not associated with a significant increase in these 3 adverse effects compared with palonosetron or on-

# Α

A	_					_			
Study or Subgroup	Ramosetr Events	ron Pa Total	alonosetron/Or Events		Wein		isk Ratio Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% Cl	
4.2.1 PACU	Liono	rotai	Liono	Total			The office of th		-
Roh (2014)	1	98	2	98	3.4		50 [0.05, 5.42]		
Subtotal (95% CI) Total events	1	98	2	98	3.4	% 0.:	50 [0.05, 5.42]		
Heterogeneity: Not a			-						
Test for overall effect	t: Z = 0.57 (P =	= 0.57)							
4.2.2 Postop- 0-6 ho	urs								
Choi (2008)	10	47	11	47	19.0		91 [0.43, 1.93]		
Roh (2014) Subtotal (95% CI)	5	98 145	9	98 145	15.5 34.5		56 [0.19, 1.60] 75 <b>[0.41, 1.39]</b>		
Total events	15	110	20	110	0 110		0 [0111, 100]		
Heterogeneity: Chi <sup>2</sup> =			5); I² = 0%						
Test for overall effect	L Z = 0.92 (P	= 0.36)							
4.2.3 Postop- 6-24 h								_	
Choi (2008) Roh (2014)	5 7	47 98	13 8	47 98	22.4 13.8		38 [0.15, 0.99] 88 [0.33, 2.32]		
Subtotal (95% CI)		145	0	145	36.2		57 [0.29, 1.11]	-	
Total events	12		21						
Heterogeneity: Chi <sup>2</sup> = Test for overall effect			i); I*= 29%						
		,							
4.2.4 Postop- 24-48 Choi (2008)	hours 2	47	3	47	5.2	o. n	67 [0.12, 3.81]		
Roh (2014)	6	98	10	98	17.2		60 [0.23, 1.59]		
Subtotal (95% CI)		145		145	22.4	% 0.6	62 [0.26, 1.44]		
Total events Heterogeneity: Chi² =	8 = 0.01 df = 1	(P = 0.92	13 2): 1= 0%						
Test for overall effect			.),1 = 0.0						
4.2.5 Postop- 48-72	hours								
Roh (2014)	2	98	2	98	3.4	% 1.	00 [0.14, 6.96]		
Subtotal (95% CI)		98		98	3.4		00 [0.14, 6.96]		
Total events Heterogeneity: Not a	2 nnlicable		2						
Test for overall effect		= 1.00)							
Total (95% CI)		631		631	100.0	o/ 0/	6 10 45 0 061		
Total events	38	031	58	031	100.0	70 0.0	6 [0.45, 0.96]	•	
Heterogeneity: Chi <sup>2</sup> =	= 2 63 df = 7	(P = 0.92)	$2) \cdot 1^2 = 0.96$				-		
			.y, i = 0.0					0.05 0.2 1 5 20	
Test for overall effect	t: Z = 2.15 (P =	= 0.03)		6) I²= 0%				0.05 0.2 1 5 20 Favours (experimental) Favours (control)	
	t: Z = 2.15 (P =	= 0.03)		6). I² = 0%					
Test for overall effect	t:Z=2.15 (P fferences:Ch	= 0.03) ni² = 0.60	. df= 4 (P = 0.9		on			Favours [experimental] Favours [control]	
Test for overall effect Test for subaroup di B Study or Subgroup	t: Z = 2.15 (P : fferences: Ch Ramose	= 0.03) ni² = 0.60	. df = 4 (P = 0.9 Palonosetro	n/Ondansetr		Weight	Mean Difference IV, Random, 95	Favours (experimental) Favours (control)	
Test for overall effect Test for subgroup di B Study or Subgroup 6.1.1 Postop- PACU	t: Z = 2.15 (P fferences: Ch Ramose <u>Mean S</u>	= 0.03) hi <sup>2</sup> = 0.60 etron <u>D Total</u>	. df = 4 (P = 0.9 Palonosetro Mean	n/Ondansetr SD	Total		Mean Difference IV, Random, 95	Favours [experimental] Favours [control] e Mean Difference % CI IV, Random, 95% CI	
Test for overall effect Test for subaroup di B Study or Subgroup	t: Z = 2.15 (P : fferences: Ch Ramose	= 0.03) hi <sup>2</sup> = 0.60 etron <u>D Total</u>	. df= 4 (P = 0.9 Palonosetro <u>Mean</u> 3	n/Ondansetr		<u>Weight</u> 16.0% <b>16.0</b> %	Mean Differenc	Favours [experimental] Favours [control]  e Mean Difference <u>% Cl IV. Random, 95% Cl</u> .53]	_
Test for overall effect Test for subgroup di B <u>Study or Subgroup</u> 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogenity: Not a	t: Z = 2.15 (P fferences: Ch <u>Ramose</u> <u>Mean S</u> 3.1 1. pplicable	etron <u>D Total</u> .6 98 98	. df= 4 (P = 0.9 Palonosetro <u>Mean</u> 3	n/Ondansetr SD	<u>Total</u> 98	16.0%	Mean Differenc <u>IV, Random, 95</u> 0.10 [-0.33, 0	Favours [experimental] Favours [control]  e Mean Difference <u>% Cl IV. Random, 95% Cl</u> .53]	_
Test for overall effect Test for subaroup di B Study or Subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI)	t: Z = 2.15 (P fferences: Ch <u>Ramose</u> <u>Mean S</u> 3.1 1. pplicable	etron <u>D Total</u> .6 98 98	. df= 4 (P = 0.9 Palonosetro <u>Mean</u> 3	n/Ondansetr SD	<u>Total</u> 98	16.0%	Mean Differenc <u>IV, Random, 95</u> 0.10 [-0.33, 0	Favours [experimental] Favours [control]  e Mean Difference <u>% Cl IV. Random, 95% Cl</u> .53]	
Test for overall effect Test for subgroup di B <u>Study or Subgroup</u> 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogenity: Not a	t: Z = 2.15 (P : fferences: Ch <u>Ramose</u> <u>Mean S</u> 3.1 1. pplicable t: Z = 0.45 (P :	etron <u>D Total</u> .6 98 98	. df= 4 (P = 0.9 Palonosetro <u>Mean</u> 3	n/Ondansetr SD	<u>Total</u> 98	16.0%	Mean Differenc <u>IV, Random, 95</u> 0.10 [-0.33, 0	Favours [experimental] Favours [control]  e Mean Difference <u>% Cl IV. Random, 95% Cl</u> .53]	
Test for overall effect Test for subdroup di B Study or Subdroup 6.1.1 Postop-PACU Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008)	t: Z = 2.15 (P = fferences: Ch <u>Ramose</u> <u>Mean S</u> 3.1 1. pplicable t: Z = 0.45 (P = urs 3.9	= 0.03) hi <sup>≈</sup> = 0.60 <u>D Total</u> .6 98 98 = 0.65) 3 47	. df= 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1	n/Ondansetr SD 1.5 2.4	<u>98</u> 98 98	16.0% <b>16.0</b> % 7.2%	Mean Differenci IV. Random, 95 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0	Favours [experimental] Favours [control] e Mean Difference KCI IV. Random, 95% CI .53] .53]	
Test for overall effect Test for subgroup di B Study or Subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% C) Heterogeneity: Not a Test for overall effect 6.1.2 Postop- 0.6 ho	t: Z = 2.15 (P : fferences: Ch <u>Ramose</u> <u>Mean S</u> 3.1 1. pplicable t: Z = 0.45 (P : urs	= 0.03) hi <sup>≈</sup> = 0.60 <u>D Total</u> .6 98 98 = 0.65) 3 47	, df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6	n/Ondansetr SD 1.5	98 98 98	16.0% <b>16.0</b> %	Mean Differenc IV, Random, 95' 0.10 [-0.33, 0 0.10 [-0.33, 0	Favours [experimental] Favours [control]	
Test for overall effect Test for suboroup di B Study or Suboroup 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> :	t: Z = 2.15 (P : fferences: Ch Ramose Mean S 3.1 1. pplicable t: Z = 0.45 (P : urs 3.9 5.3 1. = 0.00; Chi <sup>2</sup> =	= 0.03) hi² = 0.60 <u>D Total</u> .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df	4.1 6	n/Ondansetr SD 1.5 2.4 1.8	<u>98</u> 98 98 47 98	16.0% <b>16.0</b> % 7.2% 14.6%	Mean Differenc <u>IV, Random, 95'</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0	Favours [experimental] Favours [control]	
Test for overall effect Test for subgroup di B Study or Subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop- 0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI)	t: Z = 2.15 (P : fferences: Ch Ramose Mean S 3.1 1. pplicable t: Z = 0.45 (P : urs 3.9 5.3 1. = 0.00; Chi <sup>2</sup> =	= 0.03) hi² = 0.60 <u>D Total</u> .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df	4.1 6	n/Ondansetr SD 1.5 2.4 1.8	<u>98</u> 98 98 47 98	16.0% <b>16.0</b> % 7.2% 14.6%	Mean Differenc <u>IV, Random, 95'</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0	Favours [experimental] Favours [control]	_
Test for overall effect Test for subbround di B Study or Subbround 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h	t: Z = 2.15 (P · fferences: Cf Mean S 3.1 1. pplicable t: Z = 0.45 (P · urs 3.9 5.3 1. = 0.00; Chi <sup>p</sup> = t: Z = 2.55 (P · ours	= 0.03) atron <u>D Total</u> .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df = 0.01)	. df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6 = 1 (P = 0.42);	n/Ondansetr SD 1.5 2.4 1.8 1 <sup>2</sup> = 0%	10tal 98 98 47 98 145	16.0% 16.0% 7.2% 14.6% 21.8%	Mean Difference <u>N. Random, 95</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0	Favours [experimental] Favours [control]	
Test for overall effect Test for subgroup di B Study or Subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop- 0-6 ho Choi (2008) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop- 6-24 h Choi (2008)	: Z = 2.15 (P- fferences: Cf Mean S 3.1 1. pplicable : Z = 0.45 (P- urs 3.9 5.3 1. = 0.00; Chi <sup>2</sup> = : Z = 2.55 (P- iours 2.7	= 0.03) ii <sup>2</sup> = 0.60 <u>ib</u> Total .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df = 0.01) 2 47	. df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6 = 1 (P = 0.42); 3.4	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3	Total 98 98 47 98 145 47	16.0% 16.0% 7.2% 14.6% 21.8%	Mean Difference <u>IV. Random, 95</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0	Favours [experimental] Favours [control]	
Test for overall effect Test for subbround di B Study or Subbround 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h	t: Z = 2.15 (P · fferences: Cf Mean S 3.1 1. pplicable t: Z = 0.45 (P · urs 3.9 5.3 1. = 0.00; Chi <sup>p</sup> = t: Z = 2.55 (P · ours	= 0.03) ii <sup>2</sup> = 0.60 <u>ib</u> Total .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df = 0.01) 2 47	4.1 6 4.1 6 = 1 (P = 0.42); 3.4 4.7	n/Ondansetr SD 1.5 2.4 1.8 1 <sup>2</sup> = 0%	10tal 98 98 47 98 145	16.0% 16.0% 7.2% 14.6% 21.8%	Mean Difference <u>N. Random, 95</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0	Favours [experimental]         Favours [control]           se         Mean Difference <u>% Cl         IV. Random, 95% Cl</u> 1.53]	
Test for overall effect Test for subdround di B Study or Subdround di Context of Subdround di Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> :	t: Z = 2.15 (P- fferences: Cf Mean S 3.1 1. pplicable t: Z = 0.45 (P- urs 3.9 5.3 1. = 0.00; Chi <sup>2</sup> = 2.55 (P- ours 2.7 4 1. = 0.00; Chi <sup>2</sup> = 0	= 0.03) = 0.03) = 0.60 <b>D Total</b> .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df = 0.01) 2 47 .9 98 145 = 0.65	. df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6 = 1 (P = 0.42); 3.4 4.7	n/Ondansetr SD 1.5 2.4 1.8 P = 0% 2.3 2	Total 98 98 47 98 145 47 98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1%	Mean Difference <u>IV. Random. 957</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0	Favours [experimental]         Favours [control]           se         Mean Difference <u>% Cl         IV. Random, 95% Cl</u> 1.53]	
Test for overall effect Test for suboroup di B Study or Subgroup 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI)	t: Z = 2.15 (P- fferences: Cf Mean S 3.1 1. pplicable t: Z = 0.45 (P- urs 3.9 5.3 1. = 0.00; Chi <sup>2</sup> = 2.55 (P- ours 2.7 4 1. = 0.00; Chi <sup>2</sup> = 0	= 0.03) = 0.03) = 0.60 <b>D Total</b> .6 98 98 = 0.65) 3 47 .9 98 145 = 0.65, df = 0.01) 2 47 .9 98 145 = 0.65	. df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6 = 1 (P = 0.42); 3.4 4.7	n/Ondansetr SD 1.5 2.4 1.8 P = 0% 2.3 2	Total 98 98 47 98 145 47 98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1%	Mean Difference <u>IV. Random. 957</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0	Favours [experimental]         Favours [control]           se         Mean Difference <u>% Cl         IV. Random, 95% Cl</u> 1.53]	
Test for overall effect Test for subaroup di B Study or Subaroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop- 24.48	z = 2.15 (P) fferences: Cf Mean S 3.1 1. pplicable z = 0.45 (P) z = 0.45 (P) z = 0.00; Chi2 = 2.55 (P) ours 2.7 4 1. = 0.00; Chi <sup>2</sup> = 2.96 (P) t. Z = 2.96 (P) hours	- 0.03) 1 <sup>17</sup> = 0.60 217 - 0.60 217 - 0.60 218 - 0.65 219 - 0.65 219 - 0.65 219 - 0.65 219 - 0.01 219 - 0.01 219 - 0.00 219 - 0	df = 4 (P = 0.9 Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00);	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3 2 I <sup>2</sup> = 0%	145 145	16.0% 16.0% 14.6% 21.8% 9.5% 14.1% 23.6%	Mean Difference <u>IV</u> , Random, 95' 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.55, -0 -0.70 [-1.16, -0	Favours [experimental]     Favours [control]       se     Mean Difference       ½ Cl     IV. Random, 95% Cl       1.53]     Image: second seco	
Test for overall effect Test for subbround di B Study or Subbround 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008)	z = 2.15 (P- freences: Cf Mean S 3.1 1. pplicable z = 0.45 (P- urs 3.9 5.3 1. = 0.00; Ch <sup>2</sup> = z = 2.55 (P- tours 2.7 4 1. = 0.00; Ch <sup>2</sup> = z = 2.96 (P- hours 1.3 1.	= 0.03) µ <sup>™</sup> = 0.60 <u>D Total</u> 16 98 98 98 98 98 98 98 98 98 98	. df = 4 (P = 0.9 Palonosetro <u>Mean</u> 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1	n/Ondansetr SD 1.5 2.4 1.8 P = 0% 2.3 2 P = 0% 2.5	Total 98 98 98 47 98 145 47 98 145 47	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1% 23.6%	Mean Difference N. Random, 957 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.16, -0 -1.80 [-2.63, -0	Favours [experimental]     Favours [control]       se     Mean Difference       ½ Cl     IV. Random, 95% Cl       1.53]     Image: second seco	
Test for overall effect Test for subaroup di B Study or Subaroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop- 24.48	z = 2.15 (P) fferences: Cf Mean S 3.1 1. pplicable z = 0.45 (P) z = 0.45 (P) z = 0.00; Chi2 = 2.55 (P) ours 2.7 4 1. = 0.00; Chi <sup>2</sup> = 2.96 (P) t. Z = 2.96 (P) hours	= 0.03) µ <sup>™</sup> = 0.60 <u>D Total</u> 1.6 98 98 98 98 98 98 98 98 98 98	df = 4 (P = 0.9 Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3 2 I <sup>2</sup> = 0%	145 145	16.0% 16.0% 14.6% 21.8% 9.5% 14.1% 23.6%	Mean Difference <u>IV</u> , Random, 95' 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.55, -0 -0.70 [-1.16, -0	Favours [experimental] Favours [control]	
Test for overall effect Test for subbround if B Study or Subbround if Contemportal Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> :	z = 2.15 (P freences: Cf mean s 3.1 1. pplicable z = 0.45 (P urs 3.9 5.3 1. = 0.00; Ch <sup>2</sup> = z = 2.55 (P tours 2.7 4 1. = 0.00; Ch <sup>2</sup> = z = 2.55 (P tours 1.3 1. 3.7 1. = 0.48; Ch <sup>2</sup> =	= 0.03) i <sup>T</sup> = 0.60 <b>b</b> Total <b>D</b> Total <b>D</b> Total <b>D</b> Total <b>B</b> 98 = 0.65) 3 47 9 98 = 0.65, d7 47 5 0.00, d7 = 0.00, d7 = 0.003) 5 47 -8.898 -145 -5.47 -8.898 -5.47 -8.898 -5.47 -5.	df = 4 (P = 0.9 Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3 2 I <sup>2</sup> = 0% 2.5 2	Total 98 98 98 145 145 145 145	16.0% 16.0% 14.6% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3%	Mean Difference <u>IV. Random, 95'</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.70 [-1.25, -0 -0.70 [-1.57, 0 -0.70 [-1.56, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0	Favours [experimental] Favours [control]	
Test for overall effect Test for subgroup 6.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop- 0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop- 24-48 Choi (2008) Roh (2014) Subtotal (95% CI)	z = 2.15 (P freences: Cf mean s 3.1 1. pplicable z = 0.45 (P urs 3.9 5.3 1. = 0.00; Ch <sup>2</sup> = z = 2.55 (P tours 2.7 4 1. = 0.00; Ch <sup>2</sup> = z = 2.55 (P tours 1.3 1. 3.7 1. = 0.48; Ch <sup>2</sup> =	= 0.03) i <sup>T</sup> = 0.60 <b>b</b> Total <b>D</b> Total <b>D</b> Total <b>D</b> Total <b>B</b> 98 = 0.65) 3 47 9 98 = 0.65, d7 47 5 0.00, d7 = 0.00, d7 = 0.003) 5 47 -8.898 -145 -5.47 -8.898 -5.47 -8.898 -5.47 -5.	df = 4 (P = 0.9 Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3 2 I <sup>2</sup> = 0% 2.5 2	Total 98 98 98 145 145 145 145	16.0% 16.0% 14.6% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3%	Mean Difference <u>IV. Random, 95'</u> 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.70 [-1.25, -0 -0.70 [-1.57, 0 -0.70 [-1.56, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0	Favours [experimental] Favours [control]	
Test for overall effect Test for suboroun di B Study or Suboroun di Contemporal (14) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.5 Postop-48.72	$Z = 2.15 (P)^{-1}$ fferences: Cf mean s 3.1 1. pplicable $Z = 0.45 (P)^{-1}$ urs 3.9 5.3 1. $= 0.00; Ch ^2 = 1$ $Z = 2.55 (P)^{-1}$ ours 2.7 4 1. $= 0.00; Ch ^2 = 1$ $Z = 2.96 (P)^{-1}$ hours 1.3 1. 3.7 1. $= 0.48; Ch ^2 = 1$ $Z = 2.19 (P)^{-1}$	= 0.03) iP = 0.60 tron D Total 6 98 98 = 0.65) 3 47 9 98 = 0.65) 3 47 9 98 = 0.65, d7 145 0.00, d7 145 = 0.03) 5 47 8 98 145 = 0.03)	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03);	n/Ondansetr SD 1.5 2.4 1.8 P <sup>2</sup> = 0% 2.3 2 P <sup>2</sup> = 0% 2.5 2 P <sup>2</sup> = 79%	Total         98           98         98           47         98           145         47           98         145           47         98           145         145           47         98           145         145	16.0% 16.0% 7.2% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3% 24.3%	Mean Difference IV. Random, 95' 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22,-0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.54, -0 -0.70 [-1.24, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -1.20 [-2.28, -0	Favours [experimental]     Favours [control]       re     Mean Difference       % CI     IV, Random, 95% CI       153]     Image: Cliphone Circle       161]     Image: Cliphone Circle       171]     Image: Cliphone Circle       181]     Image: Cliphone Circle       193]     Image: Cliphone Circle       197]     Image: Cliphone Circle       198]     Image: Cliphone Circle       199]     Image: Cliphone Circle       191]     Image: Cliphone Circle       192]     Image: Cliphone Circle       193]     Image: Cliphone Circle       193]     Image: Cliphone Circle       193]     Image: Cli	
Test for overall effect Test for subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop- 0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop- 24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop- 24.48 Choi (2008) Roh (2014)	$Z = 2.15 (P)^{-1}$ fferences: Cf mean s 3.1 1. pplicable $Z = 0.45 (P)^{-1}$ urs 3.9 5.3 1. $= 0.00; Ch ^2 = 1$ $Z = 2.55 (P)^{-1}$ ours 2.7 4 1. $= 0.00; Ch ^2 = 1$ $Z = 2.96 (P)^{-1}$ hours 1.3 1. 3.7 1. $= 0.48; Ch ^2 = 1$ $Z = 2.19 (P)^{-1}$	= 0.03) i <sup>T</sup> = 0.60 <b>Xtron</b> <b>D</b> Total 6 98 98 = 0.65) 3 47 9 98 145 = 0.65, dr = 0.01) 2 47 9 98 145 = 0.00, dr = 0.003) 3 47 = 0.01) 2 47 9 98 145 = 0.00, dr = 0.003) 2 47 = 0.00, dr = 0.00, dr	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03); 4.5	n/Ondansetr SD 1.5 2.4 1.8 I <sup>2</sup> = 0% 2.3 2 I <sup>2</sup> = 0% 2.5 2	Total         98         98         98         98         98         98         145         145         145         145         145         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         <	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3% 24.3%	Mean Difference N. Random, 95' 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.16, -0 -1.80 [-2.63, -0 -0.70 [-1.23, -0 -1.20 [-2.28, -0 -0.80 [-1.33, -0	Favours [experimental]     Favours [control]       re     Mean Difference       ½ Cl     N. Random, 95% Cl       1.53]	
Test for overall effect Test for suboroun di B Study or Suboroun di Contemporal (14) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.5 Postop-48.72	$\begin{array}{c} z = 2.15 \ (\text{P} \cdot z \\ \hline \text{ferences: Cf} \\ \hline \text{ferences: Cf} \\ \hline \text{mean sc} \\ 3.1 & 1. \\ pplicable \\ z = 0.45 \ (\text{P} \cdot z \\ 0.00; \text{Ch}^{\text{P}} = \\ z = 2.55 \ (\text{P} \cdot z \\ 0.00; \text{Ch}^{\text{P}} = \\ z = 2.55 \ (\text{P} \cdot z \\ 0.00; \text{Ch}^{\text{P}} = \\ z = 2.96 \ (\text{P} \cdot z \\ 1.3 & 1. \\ 3.7 & 1. \\ = 0.48; \text{Ch}^{\text{P}} = \\ z = 2.19 \ (\text{P} \cdot z \\ 0.00;$	= 0.03) iP = 0.60 tron D Total 6 98 98 = 0.65) 3 47 9 98 = 0.65) 3 47 9 98 = 0.65, d7 145 0.00, d7 145 = 0.03) 5 47 8 98 145 = 0.03)	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03); 4.5	n/Ondansetr SD 1.5 2.4 1.8 P <sup>2</sup> = 0% 2.3 2 P <sup>2</sup> = 0% 2.5 2 P <sup>2</sup> = 79%	Total         98           98         98           47         98           145         47           98         145           47         98           145         145           47         98           145         145	16.0% 16.0% 7.2% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3% 24.3%	Mean Difference IV. Random, 95' 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22,-0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.54, -0 -0.70 [-1.24, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -1.20 [-2.28, -0	Favours [experimental]     Favours [control]       re     Mean Difference       ½ Cl     N. Random, 95% Cl       1.53]	
Test for overall effect Test for subbroup di B Study or Subbroup di C.1.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect C.1.2 Postop-0.6 Ch Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect C.1.3 Postop-0.624 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect C.1.4 Postop-24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Subtotal (95% CI)	z = 2.15 (P) fferences: Cf <b>Ramose</b> <b>Mean S</b> 3.1 1. pplicable z = 0.45 (P) <b>urs</b> 3.9 5.3 1. $z = 0.00; Ch ^2 = 2.55 (P)$ <b>ours</b> 2.7 4 1. $z = 0.00; Ch ^2 = 2.96 (P)$ <b>hours</b> 1.3 1. 3.7 1. $z = 0.48; Ch ^2 = 2.19 (P)$ <b>hours</b> 3.7 pplicable	= 0.03) iP = 0.60 <b>tron</b> <b>D</b> Total 6 98 98 = 0.65) 3 47 9 98 145 = 0.65, df 145 = 0.05, df 145 = 0.00, df = 0.003) 5 47 = 0.003) 145 = 0.003) 145 = 0.003) 2 47 = 0.003) 145 = 0.0030 145 = 0	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03); 4.5	n/Ondansetr SD 1.5 2.4 1.8 P <sup>2</sup> = 0% 2.3 2 P <sup>2</sup> = 0% 2.5 2 P <sup>2</sup> = 79%	Total         98         98         98         98         98         145         145         145         145         145         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98         145         98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3% 24.3%	Mean Difference N. Random, 95' 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.16, -0 -1.80 [-2.63, -0 -0.70 [-1.23, -0 -1.20 [-2.28, -0 -0.80 [-1.33, -0	Favours [experimental]     Favours [control]       re     Mean Difference       ½ Cl     N. Random, 95% Cl       1.53]	
Test for overall effect Test for subbround if B Study or Subbround if Contemporal and the subbround if Subtotal (95% CI) Heterogeneity: Not a Test for overall effect Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Ch.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Ch.1.4 Postop- 24.48 Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Choi (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect Ch.1.5 Postop- 48-72 Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect	z = 2.15 (P) fferences: Cf <b>Ramose</b> <b>Mean S</b> 3.1 1. pplicable z = 0.45 (P) <b>urs</b> 3.9 5.3 1. $z = 0.00; Ch ^2 = 2.55 (P)$ <b>ours</b> 2.7 4 1. $z = 0.00; Ch ^2 = 2.96 (P)$ <b>hours</b> 1.3 1. 3.7 1. $z = 0.48; Ch ^2 = 2.19 (P)$ <b>hours</b> 3.7 pplicable	= 0.03) i <sup>T</sup> = 0.60 <b>b</b> Total <b>D</b> Total	. df = 4 (P = 0.9 Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03); 4.5	n/Ondansetr SD 1.5 2.4 1.8 P <sup>2</sup> = 0% 2.3 2 P <sup>2</sup> = 0% 2.5 2 P <sup>2</sup> = 79%	Total         98           98         98           47         98           145         47           98         145           47         98           145         98           98         98           98         98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.3% 24.3% 14.3%	Mean Difference IV. Random, 95' 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.25, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -0.80 [-1.33, -0 -0.80 [-1.33, -0	Favours [experimental]     Favours [control]       re     Mean Difference       % Cl     N, Random, 95% Cl       153]	_
Test for overall effect Test for subbroun di B Study or Subbroun di Ch.1 Postop-PACU Roh (2014) Subtotal (95% CI) Heterogeneity: Not a Test for overall effect 6.1.2 Postop-0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.3 Postop-6-24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.4 Postop-24-48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.5 Postop-48-72 Roh (2014) Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> : Test for overall effect 6.1.5 Postop-48-72 Roh (2014) Subtotal (95% CI) Heterogeneity: Rufe Total (95% CI)	$\begin{array}{c} z = 2.15 \ (P)^- \\ \mbox{ferences: Cf} \\ \hline \mbox{Remose} \\ \mbox{Mean} & \mathbf{S} \\ \mbox{3.1} & 1, \\ \mbox{pplicable} \\ \mbox{is } z = 0.45 \ (P)^- \\ \mbox{urs} \\ \mbox{3.9} \\ \mbox{5.3} & 1, \\ \mbox{e} z = 0.45 \ (P)^- \\ \mbox{is } z = 2.55 \ (P)^- \\ \mbox{is } z = 2.55 \ (P)^- \\ \mbox{is } z = 2.96 \ (P)^- \\ \mbox{hours} \\ \mbox{1.3} & 1, \\ \mbox{3.7} & 1, \\ \mbox{e} z = 2.94 \ (P)^- \\ \mbox{pplicable} \\ \mbox{is } z = 2.94 \ (P)^- \\ \mbox{e} z = 0.17, \ Ch^2 = \\ \mbox{e} z = 0.17, \ Ch^2 = \\ \mbox{e} z = 2.94 \ (P)^- \\ \mbox{e} z = 2.94 \ (P$	= 0.03) i <sup>1</sup> = 0.60 <b>2tron</b> <b>D</b> Total <b>6</b> 98 <b>98</b> = 0.65) <b>3</b> 47 <b>9</b> 98 <b>145</b> = 0.65, df = 0.01) <b>2</b> 47 <b>7</b> 9 <b>98</b> <b>145</b> = 0.65, df = 0.01) <b>2</b> 47 <b>7</b> 9 <b>98</b> <b>145</b> = 0.00, df <b>145</b> = 0.00, df = 0.00, df <b>145</b> = 0.00, df = 0.00, df = 0.00, df = 0.00, df = 0.00, df = 0.00, df =	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 1.00); 3.1 4.4 = 1 (P = 0.03); 4.5 df = 7 (P = 0.003)	n/Ondansetr SD 1.5 2.4 1.8 P = 0% 2.3 2 P = 0% 2.5 2 P = 79% 1.8	Total         98           98         98           47         98           145         47           98         145           47         98           145         98           98         98           98         98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.1% 23.6% 9.9% 14.3% 24.3%	Mean Difference N. Random, 95' 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.16, -0 -1.80 [-2.63, -0 -0.70 [-1.23, -0 -1.20 [-2.28, -0 -0.80 [-1.33, -0	Favours [experimental]     Favours [control]       re     Mean Difference       K.Cl     N, Random, 95% Cl       153]	_
Test for overall effect Test for subgroup 6.1.1 Postop- PACU Roh (2014) Subtotal (95% CI) Heterogeneity. Not a Test for overall effect 6.1.2 Postop- 0.6 ho Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity. Tau <sup>2</sup> . Test for overall effect 6.1.3 Postop- 6.24 h Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity. Tau <sup>2</sup> . Test for overall effect 6.1.4 Postop- 24.48 Choi (2008) Roh (2014) Subtotal (95% CI) Heterogeneity. Tau <sup>2</sup> . Test for overall effect 6.1.5 Postop- 48-72 Roh (2014) Subtotal (95% CI)	z = 2.15 (P) fferences: Cf <b>Ramose</b> <b>Mean S</b> 3.1 1. pplicable z = 0.45 (P) <b>urs</b> 3.9 5.3 1. z = 0.00; Ch  <sup>2</sup> = z = 2.55 (P) <b>ours</b> 1.3 1. 3.7 1. z = 0.00; Ch  <sup>2</sup> = z = 2.96 (P) <b>hours</b> 3.7 pplicable z = 2.94 (P) <b>hours</b> 3.7 pplicable z = 2.94 (P) z = 0.47; Ch  <sup>2</sup> = z = 2.356 (P)	= 0.03) i <sup>T</sup> = 0.60 i <sup>T</sup> = 0.60 i <sup>T</sup> = 0.60 i <sup>T</sup> = 0.60 i <sup>T</sup> = 0.65 i <sup>3</sup> = 7, 9 i <sup>45</sup> = 0.65, i <sup>47</sup> i <sup>45</sup> = 0.65, i <sup>47</sup> i <sup>45</sup> = 0.05, i <sup>47</sup> i <sup>45</sup> = 0.05, i <sup>47</sup> i <sup>45</sup> = 0.00, i <sup>47</sup> i <sup>47</sup>	df = 4 (P = 0.9) Palonosetro Mean 3 4.1 6 = 1 (P = 0.42); 3.4 4.7 = 1 (P = 0.02); 3.1 4.4 = 1 (P = 0.03); 4.5 $df = 7 (P = 0.003)$	n/Ondansetr SD 1.5 1.5 1.8 1?= 0% 2.3 2 1?= 0% 2.5 2 1.8 1.8 1.8 1.8	Total         98           98         98           47         98           145         145           47         98           145         98           145         98           98         98           98         98           98         98           98         98           98         98           98         98           98         98           98         98	16.0% 16.0% 7.2% 14.6% 21.8% 9.5% 14.3% 24.3% 14.3%	Mean Difference IV. Random, 95' 0.10 [-0.33, 0 0.10 [-0.33, 0 -0.20 [-1.30, 0 -0.70 [-1.22, -0 -0.61 [-1.08, -0 -0.70 [-1.57, 0 -0.70 [-1.57, 0 -0.70 [-1.25, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -0.70 [-1.23, -0 -0.80 [-1.33, -0 -0.80 [-1.33, -0	Favours [experimental]     Favours [control]       re     Mean Difference       % Cl     N, Random, 95% Cl       153]	_

Figure 3. (A) Forrest plot of rescue antiemetics. (B) Forrest plot of postoperative pain score.

dansetron after spinal surgery. These findings are consistent with those of Roh et al<sup>14</sup> who reported no considerable differences in other adverse events, including constipation, urinary retention, and pruritus, and Song et al<sup>13</sup> who reported no differences in palpitation. Evidence also suggests that 5-HT3 receptor antagonists can increase the risk of cardiac injury in patients receiving chemotherapy.<sup>23</sup> Adverse events associated with these medications include decreased heart rate and a prolonged QT interval.<sup>24</sup> None of the included studies in this meta-analysis reported severe cardiac ad-

verse events, such as PR interval prolongation, fatal arrhythmias, or sudden cardiac death.

This meta-analysis has some limitations that should be noted. First, the numbers of RCTs and patients analyzed in our study were relatively small as our literature search was restricted to English language studies that included adult patients. These limitations may have led to selection bias. Further, the ethnicity of the patients was restricted to only Asians. This is an important consideration for future studies because ethnicity can influence the

#### Table 3

Sensitivity analysis of outcomes.

Outcome	Analysis method	Fixed-effect model (95% CI)	Random-effect model (95% CI)
Postoperative nausea and vomiting	RR	0.86 (0.76 to 0.97)	0.87 (0.77 to 0.98)
Postoperative nausea	RR	0.94 (0.84 to 1.06)	0.94 (0.80 to 1.11)
PACU	RR	0.78 (0.41 to 1.47)	0.78 (0.41 to 1.47)
0-6 h	RR	1.02 (0.85 to 1.21)	1.02 (0.69 to 1.50)
6-24 h	RR	0.93 (0.78 to 1.11)	0.95 (0.80 to 1.13)
24-48 h	RR	0.72 (0.49 to 1.05)	0.72 (0.49 to 1.05)
48-72 h	RR	2.00 (0.71 to 5.64)	2.00 (0.71 to 5.64)
Postoperative vomiting	RR	0.32 (0.19 to 0.56)	0.36 (0.21 to 0.64)
PACU	RR	Not estimated	Not estimated
0-6 h	RR	0.17 (0.06 to 0.52)	0.17 (0.06 to 0.52)
6-24 h	RR	0.41 (0.19 to 0.86)	0.41 (0.19 to 0.86)
24-48 h	RR	1.00 (0.21, to 4.87)	1.00 (0.21 to 4.87)
48-72 h	RR	0.33 (0.01 to 8.08)	0.33 (0.01 to 8.08)
Rescue antiemetic	RR	0.66 (0.45 to 0.96)	0.67 (0.45 to 0.98)
PACU	RR	0.50 (0.05 to 5.42)	0.50 (0.05 to 5.42)
0-6 h	RR	0.75 (0.41 to 1.39)	0.77 (0.42 to 1.42)
6-24 h	RR	0.57 (0.29 to 1.11)	0.58 (0.26 to 1.29)
24-48 h	RR	0.62 (0.26 to 1.44)	0.62 (0.26 to 1.44)
48-72 h	RR	1.00 (0.14 to 6.96)	1.00 (0.14 to 6.96)
Patient-controlled analgesia discontinuation	RR	0.76 (0.41 to 1.40)	0.76 (0.41, 1.40)
Pain score	MD	-0.58 (-0.79 to -0.37)	-0.66 (-1.02 to -0.30)
PACU	MD	0.10 (-0.33 to 0.53)	0.10 (-0.33 to 0.53)
0-6 h	MD	-0.61 (-1.08 to -0.14)	-0.61 (-1.08 to -0.14)
6-24 h	MD	-0.70 (-1.16 to -0.24)	-0.70 (-1.16 to -0.24)
24-48 h	MD	-1.02 (-1.47 to -0.57)	-1.20 (-2.28 to -0.13)
48-72 h	MD	-0.80 (-1.33 to -0.27)	-0.80 (-1.33 to -0.27)
Rescue analgesics	RR	0.97 (0.85 to 1.12)	0.90 (0.58 to 1.40)
Rescue pain medications	MD	-2.63(-8.46  to  3.21)	-9.43 (-32.30 to 13.44)
Adverse events	RR	1.10 (0.80 to 1.51)	1.08 (0.72 to 1.61)
Headache	RR	0.78 (0.44 to 1.41)	0.80 (0.44 to 1.44)
Dizziness	RR	0.94 (0.59 to 1.49)	0.95 (0.60 to 1.51)
Drowsiness	RR	1.17 (0.78 to 1.75)	1.17 (0.78 to 1.76)

MD = mean difference; PACU = postanesthesia care unit; RR = relative risk.

risk of PONV,<sup>25,26</sup> and there have been reports that genetic factors in certain ethnicities can either protect against PONV, predispose individuals to motion sickness, or influence those who have had a previous surgery with PONV. And there are also pharmacogenetic differences between Asian and non-Asian patients.<sup>25,26</sup> Secondly, postoperative pain was only measured using a pain score without distinguishing resting pain from nonresting pain. The degree of pain can differ depending on the activity of the individual and therefore must be considered when assessing pain severity. Further studies are needed to address these limitations and better understand the value of ramosetron following spinal surgery.

### Conclusions

This meta-analysis of 3 RCTs showed that ramosetron reduced the risk of PONV and POV, limited the use of rescue antiemetics, reduced the postoperative pain score, and did not increase the risk of PCA discontinuation compared with palonosetron or ondansetron after spinal surgery in 3 RCTs. No significant differences between ramosetron and either palonosetron or ondansetron were found with regard to the incidence of PON, use of rescue pain medications, or rescue analgesics required. Therefore, this meta-analysis indicates that ramosetron is an effective and welltolerated antiemetic that could be used to prevent PONV following spinal surgery in adult patients.

# **Conflicts of Interest**

The authors have indicated that they have no conflicts of interest regarding the content of this article.

#### **CRediT** authorship contribution statement

Yiyun Lin: Conceptualization, Data curation, Formal analysis, Methodology, Software, Writing – original draft. Sun Tiansheng: Conceptualization, Supervision. Zhang Zhicheng: Data curation, Formal analysis, Software. Chen Xiaobin: Data curation, Formal analysis, Methodology, Software, Writing – review & editing. Li Fang: Methodology, Supervision.

# Acknowledgments

The authors thank Medjaden Inc (https://en.medjaden.com) for providing English language editing.

L. Yiyun contributed to conceptualization, data curation, formal analysis, methodology, software, and writing (original draft); S. Tiansheng contributed to conceptualization and supervision;

Z. Zhicheng contributed to data curation, formal analysis, and software; C. Xiaobin contributed to data curation, formal analysis, methodology, software, and writing (review and editing); and L. Fang contributed to methodology and supervision.

#### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.curtheres.2022. 100666.

#### References

- Bajwa SJ, Haldar R. Pain management following spinal surgeries: An appraisal of the available options. *Journal of craniovertebral junction & spine*. 2015;6(3):105– 110. doi:10.4103/0974-8237.161589.
- Elvir-Lazo OL, White PF, Yumul R, Cruz Eng H. Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review. *F1000Res*. 2020;9. doi:10.12688/f1000research.21832.1.

- Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. *Anesthe*sia and analgesia. 2014;118(1):85–113. doi:10.1213/ANE.000000000000002.
- Wiesmann T, Kranke P, Eberhart L. Postoperative nausea and vomiting a narrative review of pathophysiology, pharmacotherapy and clinical management strategies. *Expert opinion on pharmacotherapy*. 2015;16(7):1069–1077. doi:10. 1517/14656566.2015.1033398.
- Samieirad S, Sharifian-Attar A, Eshghpour M, Mianbandi V, Shadkam E, Hosseini-Abrishami M, et al. Comparison of Ondansetron versus Clonidine efficacy for prevention of postoperative pain, nausea and vomiting after orthognathic surgeries: A triple blind randomized controlled trial. *Med Oral Patol Oral Cir Bucal.* 2018;23(6):e767–ee76. doi:10.4317/medoral.22493.
- Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A, et al. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. *BMC medicine*. 2015;13:136. doi:10.1186/s12916-015-0371-y.
- Yokoi A, Mihara T, Ka K, Goto T. Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: An updated systematic review and meta-analysis with trial sequential analysis. *PloS one*. 2017;12(10):e0186006. doi:10.1371/journal.pone.0186006.
- Gao C, Li B, Xu L, Lv F, Cao G, Wang H, et al. Efficacy and safety of ramosetron versus ondansetron for postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized clinical trials. *Drug design, development* and therapy. 2015;9:2343–2350. doi:10.2147/DDDT.S80407.
- Lee SU, Lee HJ, Kim YS. The effectiveness of ramosetron and ondansetron for preventing postoperative nausea and vomiting after arthroscopic rotator cuff repair: a randomized controlled trial. *Journal of orthopaedic surgery and research*. 2020;15(1):523. doi:10.1186/s13018-020-02060-3.
- Ryu JH, Jeon YT, Min B, Hwang JY, Sohn HM. Effects of palonosetron for prophylaxis of postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: A prospective, randomized, double-blind, placebo-controlled study. *PloS one*. 2018;13(5):e0196388. doi:10.1371/journal. pone.0196388.
- Kim BG, Kim H, Lim HK, Yang C, Oh S, Lee BW. A comparison of palonosetron and dexamethasone for postoperative nausea and vomiting in orthopedic patients receiving patient-controlled epidural analgesia. *Korean journal of anesthe*siology. 2017;70(5):520–526. doi:10.4097/kjae.2017.70.5.520.
- Koh IJ, Chang CB, Jeon YT, Ryu JH, Kim TK. Does ramosetron reduce postoperative emesis and pain after TKA? *Clinical orthopaedics and related research*. 2012;470(6):1718–1727. doi:10.1007/s11999-011-2208-0.
- Song JW, Shim JK, Choi SH, Soh S, Jang J, Kwak YL. Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms. *Journal of neurosurgical anesthesiology*. 2017;29(4):406–414. doi:10.1097/ANA.000000000000361.
- 14. Roh GU, Yang SY, Shim JK, Kwak YL. Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lum-

bar spinal surgery: a prospective, randomized, and double-blind trial. Spine. 2014;39(9):E543–E549. doi:10.1097/BRS.00000000000236.

- Choi YS, Shim JK, Yoon DH, Jeon DH, Lee JY, Kwak YL. Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron. *Spine*. 2008;33(17):E602–E606. doi:10.1097/BRS.0b013e31817c6bde.
- Kim MS, Park JH, Choi YS, Park SH, Shin S. Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials. *Yonsei medical journal*. 2017;58(4):848–858. doi:10.3349/ymj.2017.58.4848.
   Ahn E, Choi G, Kang H, Baek C, Jung Y, Woo Y, et al. Palonosetron
- Ahn E, Choi G, Kang H, Baek C, Jung Y, Woo Y, et al. Palonosetron and Ramosetron Compared for Effectiveness in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. *PloS one*. 2016;11(12):e0168509. doi:10.1371/journal.pone.0168509.
- Spruce L. Using a Complementary Intervention to Decrease Postoperative Nausea and Vomiting. Aorn j. 2020;112(4):417–418. doi:10.1002/aorn.13193.
- Shaikh SI, Nagarekha D, Hegade G, Marutheesh M. Postoperative nausea and vomiting: A simple yet complex problem. *Anesthesia, essays and researches.* 2016;10(3):388–396. doi:10.4103/0259-1162.179310.
- Park SC, Chang SY, Mok S, Kim H, Chang BS, Lee CK. Risk factors for postoperative ileus after oblique lateral interbody fusion: a multivariate analysis. *The spine journal: official journal of the North American Spine Society.* 2020. doi:10.1016/j.spinee.2020.10.002.
- Wang H, Ma L, Chen Y. Analgesic effects of low-dose ketamine after spinal fusion in adults: A protocol of prospective randomized trial. *Medicine*. 2020;99(38):e22162. doi:10.1097/MD.00000000022162.
- 22. Park YH, Jang YE, Byon HJ, Kim JT, Kim HS. Comparison of the efficacy of ramosetron and ondansetron in the prophylaxis of postoperative vomiting in children receiving fentanyl by patient-controlled analgesia after orthopedic surgery: a randomized controlled trial. *Paediatric anaesthesia*. 2013;23(4):360– 364. doi:10.1111/pan.12103.
- Pinarli FG, Elli M, Dagdemir A, Baysal K, Acar S. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. *Pediatr Blood Cancer*. 2006;47(5):567–571. doi:10.1002/pbc.20639.
- Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. *BMC medicine*. 2015;13:142. doi:10.1186/s12916-015-0379-3.
- Klenke S, de Vries GJ, Schiefer L, Seyffert N, Bachmann HS, Peters J, et al. Genetic contribution to PONV risk. *Anaesth Crit Care Pain Med*. 2020;39(1):45–51. doi:10.1016/j.accpm.2019.04.012.
- Klenke S, Frey UH. Genetic variability in postoperative nausea and vomiting: A systematic review. European journal of anaesthesiology. 2020;37(11):959–968. doi:10.1097/eja.00000000001224.